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ABSTRACT 
 
Patrick L. Sheets 
 
 
 
Electrophysiological and pharmacological properties of the neuronal voltage-
gated sodium channel subtype Nav1.7
 
 
 
Voltage-gated sodium channels (VGSCs) are transmembrane proteins 
responsible for the initiation of action potentials in excitable tissues by selectively 
allowing Na+ to flow through the cell membrane.  VGSC subtype Nav1.7 is highly 
expressed in nociceptive (pain-sensing) neurons.  It has recently been shown 
that individuals lacking the Nav1.7 subtype do not experience pain but otherwise 
function normally.  In addition, dysfunction of Nav1.7 caused by point mutations in 
the channel is involved in two inherited pain disorders, primary erythromelalgia 
(PE) and paroxysmal extreme pain disorder (PEPD).  This indicates Nav1.7 is a 
very important component in nociception.  The aims of this dissertation were to 1) 
investigate if the antipsychotic drug, trifluoperazine (TFP), could modulate Nav1.7 
current; 2) examine changes in Nav1.7 properties produced by the PE mutation 
N395K including sensitivity to the local anesthetic (LA), lidocaine; and 3) 
determine how different inactivated conformations of Nav1.7 affect lidocaine 
inhibition on the channel using PEPD mutations (I1461T and T1464I) that alter 
transitions between the different inactivated configurations of Nav1.7.  Standard 
whole-cell electrophysiology was used to determine electrophysiological and 
pharmacological changes in WT and mutant sodium currents.  Results from this 
dissertation demonstrate 1) TFP inhibits Nav1.7 channels through the LA 
 vii
interaction site; 2) the N395K mutation alters electrophysiological properties of 
Nav1.7 and decreases channel sensitivity to the local anesthetic lidocaine; and 3) 
lidocaine stabilizes Nav1.7 in a configuration that decreases transition to the slow 
inactivated state of the channel.  Overall, this dissertation answers important 
questions regarding the pharmacology of Nav1.7 and provides insight into the 
changes in Nav1.7 channel properties caused by point mutations that may 
contribute to abnormal pain sensations.  The results of this dissertation on the 
function and pharmacology of the Nav1.7 channel are crucial to the 
understanding of pain pathophysiology and will provide insight for the 
advancement of pain management therapies. 
 
Theodore R. Cummins, Ph.D. 
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courage and wisdom.  It is only because of problems that we grow mentally and 
spiritually.  It is through the pain of confronting and resolving problems that we 
learn.” 
 
       M. Scott Peck 1936—2005  
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I. INTRODUCTION 
A. Overview 
Pain is a serious medical problem.  The International Association for the 
Study of Pain (IASP) defines pain as an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in 
terms of such damage.  According to estimates by the American Pain Society, 75 
million people are partially or totally disabled by pain and 45% of all Americans 
seek care for persistent pain at some point in their lives.  Pain sensations 
typically originate in peripheral pain-sensing neurons known as nociceptors.  
These neurons relay information about noxious stimuli from the periphery of the 
human body to the central nervous system (CNS).  Therefore, alterations in the 
homeostasis of this process can result in increased or diminished pain 
sensations.   
Voltage-gated ion channels play a major role in determining excitability 
properties of peripheral and central neurons.  Over the last 20 years, numerous 
studies have investigated the role of different ion channels in nociception, 
hyperexcitability, and increased pain sensitivity (Matzner and Devor, 1994; Baker 
and Wood, 2001).  Although changes in ion channels of CNS neurons are likely 
to contribute to altered pain sensitivity, the vast majority of studies have focused 
on ion channels and ionic currents in the peripheral nervous system (PNS).  
Changes in the activities of many different ion channel subtypes have been 
identified in various pain models and there is evidence indicating several different 
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types of ion channels can play important roles in nociception and altered pain 
sensitivity.   
The American Medical Association has stated that repeated evaluations of 
the state of pain therapy over the past 20 years suggest that many patients 
receive inadequate pain relief.  Furthermore, pain therapeutics to date, although 
initially effective, have the potential to produce addiction, physical dependence, 
tolerance, as well as unwanted side effects.  Therefore, the research and 
discovery of unique therapeutic targets for the treatment of pain is important.  
The critical role of voltage-gated sodium channels in the function of nociceptors 
makes them an important aspect to research for the advancement of pain 
mechanism and therapeutics. 
The main focus in this dissertation is the modulation and pharmacology of 
the voltage-gated sodium channel subtype Nav1.7 found primarily in peripheral 
sensory neurons.  There is compelling support that the Nav1.7 subtype is 
involved in pain perception due to studies of individuals that appear to have a 
complete insensitivity to pain (Cox et al., 2006; Goldberg et al., 2007; Ahmad et 
al., 2007).  This provides strong evidence that complete loss of Nav1.7 function 
results in a complete inability to sense pain.  This channel is an intriguing 
component of pain-sensing neurons, and it is important to evaluate the 
pharmacology and function of Nav1.7 to better understand the mechanism of pain 
and design more specific and effective pain therapeutics.   
 
 
 2
B. Brief history and discovery of sodium channels in the nerve 
In a series of experiments using the squid giant axon, two English 
physiologists, Sir Alan L. Hodgkin and Sir Andrew F. Huxley, discovered that 
transmission of action potentials along the axon of a nerve was reliant on the 
permeability of sodium (Na+) and potassium (K+) ions across the plasma 
membrane (Hodgkin and Huxley, 1952, a, b, c, d).  In addition to these findings, 
Hodgkin and Huxley discovered that membrane voltage (or potential) of the squid 
giant axon played a role in sodium conductance and sodium current kinetics and 
suggested sodium conductance was controlled by a gating mechanism (Hodgkin 
and Huxley, 1952, b, c, d).  Thus, the term voltage-gated was born.  Some years 
later, it was discovered the Na+ current in squid giant axons could be selectively 
eliminated using a paralytic toxin called tetrodotoxin (TTX)  found in the liver of 
the puffer fish indicating a distinct pathway for Na+ ions to cross the plasma 
membrane (Narahashi et al., 1964).  Pharmacologic studies using another 
selective blocker of Na+ current, saxitoxin (STX), on frog and rabbit vagus nerve 
demonstrated the saxitoxin interacted with individual receptors to block Na+ 
current (Hille, 1968; Ritchie et al., 1976). These studies together confirmed Na+ 
current was 1) voltage-dependent; 2) controlled by different gating configurations; 
and 3) conducted by individual receptors or channels.  The scientific 
advancement of patch-clamp recording allowing the examination of Na+ currents 
in small isolated neurons (Hamill et al., 1981; Sakmann and Neher, 1984) has 
been pivotal in the understanding of the different subtypes of Na+ channels found 
in the body.  While this dissertation focuses primarily on only one voltage-gated 
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sodium channel subtype, it is important to introduce the structure, function, and 
modulation of voltage-gated sodium channels as a whole.    
C. Voltage-gated sodium channels 
Voltage-gated sodium channels (VGSC or Nav) are complex 
transmembrane proteins that allow the influx of sodium needed to initiate action 
potentials in excitable tissues (Goldin, 2001).  They are crucial for the excitability 
of neuronal, cardiac, skeletal, and smooth muscle tissue.  The primary functional 
unit of the voltage-gated sodium channel is a 220-260 kD polypeptide known as 
the α subunit.  The α subunit consists of four transmembrane domains (DI—DIV) 
with each domain consisting of six transmembrane segments (S1—S6, Figure 1).  
The S4 segments each contain four to eight basic amino acids (arginines or 
lysines) which are positively charged.  These residues are thought to respond to 
changes in membrane voltage (or potential) and can move within the membrane 
creating various gating configurations (Noda et al., 1984).  In a simplified 
scheme, VGSCs can exist in one of three gating configurations: resting (primed), 
open (activated), or inactivated (Figure 2).  Resting or primed refers to the 
configuration of VGSCs, usually at hyperpolarized (or negative) membrane 
potentials, in which the channel is capable of opening in response to 
depolarization of the membrane. Open or activated is the configuration by which 
VGSCs allow the selective passing of Na+ ions through the pore of the channel 
producing current.  Current through VGSCs is terminated within 1 or 2 
milliseconds by a process called fast-inactivation thought to occur when a DIII- 
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Figure 1.  Linear diagram of the α subunit for the Nav1.7 voltage-gated 
sodium channel.  The α subunit consists of four transmembrane domains (DI—
DIV) with each domain consisting of six transmembrane segments (S1—S6).  
This figure was created using CorelDraw version 9.   
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Figure 2.  Simplified scheme of the different states of voltage-gated sodium 
channels.  A, Voltage clamp recording from a single HEK293 cell transfected 
with Nav1.7 cDNA showing typical voltage-gated sodium currents.  The 
downward deflection reflects the inward movement of sodium ions in response to 
a depolarizing voltage pulse from a holding potential of -80 mV.  The channel is 
closed (C) at -80 mV and when pulsed to +15 mV the channel opens (O) and 
rapidly inactivates (I).  B, A simple action potential schematic indicating where in 
the action potential waveform you would expect voltage-gated sodium channels 
to be closed, open, or inactivated.  C, Diagram indicating the proposed scheme 
for voltage-gated sodium channels transitions from closed to open to fast-
inactivated.  This figure was created using CorelDraw version 9. 
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DIV cytoplasmic linker (also known as the inactivation particle shown in Figure 1) 
binds within the pore and occludes the flow of sodium ions (West et al., 1992).  In 
addition to fast inactivation, there have been studies showing a slower 
component of inactivation in neuronal (Ogata and Tatebayashi, 1992; Mickus et 
al., 1999), cardiac (Vilin et al., 1999) and skeletal muscle channels (Richmond et 
al., 1998).  This slow component of inactivation is caused by prolonged 
depolarizations and can take seconds to minutes to recover.  Fast and slow 
inactivation have both been proposed to play a role in the interaction of local 
anesthetics with VGSCs and will be discussed later.   
The inner pore of the channel is thought to consist of the S6 segments of 
each of the four domains (Fozzard and Hanck, 1996; Marban et al., 1998; 
Catterall, 2000).  Nine distinct voltage-gated sodium channel α subunits (Nav1.1-
1.9) have been cloned from mammals (Goldin, 2002), and many of these α 
subunits have specific developmental, tissue, or cellular distributions.  Nav1.4 is 
highly expressed in skeletal muscle (Trimmer et al., 1989).  Although Nav1.5 is 
predominantly expressed in cardiac muscle (Rogart et al., 1989), Nav1.5 mRNA 
and current is detectable in neonatal dorsal root ganglia (DRG) neurons 
(Renganathan et al., 2002).  Nav1.5 mRNA is also detectable in some adult DRG 
neurons but expression is considered to be very low under most conditions.  
Mature neurons typically express multiple sodium channel isoforms.  Adult CNS 
neurons may express combinations of Nav1.1, Nav1.2 and Nav1.6 (Trimmer and 
Rhodes, 2004).  Adult DRG sensory neurons can express combinations of 
Nav1.1, Nav1.6, Nav1.7, Nav1.8, and Nav1.9 (Black et al., 1996; Dib-Hajj et al., 
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1998; Amaya et al., 2000).  Nav1.3 is predominantly expressed in immature 
neurons and is normally found at very low levels in adult neurons (Beckh et al., 
1989).  However, under certain conditions Nav1.3 expression is upregulated in 
adult neurons and this may play a role in altered pain sensations (Waxman et al., 
1994; Boucher et al., 2000).  Although message for Nav1.2, one of the 
predominant CNS isoforms, is detectable in adult DRG neurons, expression is 
low in these cells under most conditions (Black et al., 1996). 
Since its discovery as a VGSC blocker, TTX has been identified as a 
highly selective blocker of CNS and skeletal muscle sodium currents (IC50 ~ 5-
20 nM; (Ritchie and Rogart, 1977)) but a relatively weak blocker of cardiac 
muscle sodium currents (IC50 ~ 1-2 µM; (Baer et al., 1976)), further confirming 
distinct VGSCs generate the sodium currents in different tissues.  Based on their 
sensitivity to TTX, VGSCs have been divided primarily into two groups, TTX-
sensitive (TTX-S) and TTX-resistant (TTX-R).  While this toxin has been useful in 
distinguishing TTX-R and TTX-S currents in neurons, it is not effective at 
isolating single VGSC subtype current in neurons.  Therefore, the use of 
heterologous (derived from tissue) cell systems such as human embryonic 
kidney cells (HEK293) are useful in examining current produced from a single 
VGSC subtype.  These cells are able to internalize expression vectors containing 
VGSC cDNA and effectively transcribe and translate the full channel and place it 
in the cell membrane.  We have shown that the naïve HEK293 cells exhibit 
negligible Na+ current.  This characteristic provides confidence that any Na+ 
current observed in voltage-clamp experiments (explained in Materials and 
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Methods) from a single HEK293 cell after internalization of cDNA is from our 
channel of interest.  Expression of the α-subunit alone is sufficient to produce 
functional sodium currents in heterologous cell systems, however β-subunits 
(Isom, 2001; Yu et al., 2003; Grieco et al., 2005) and other accessory proteins 
such as calmodulin (CaM) (Herzog et al., 2003b) or annexin II (Okuse et al., 
2002) may be important modulators of VGSCs in their native environment.  The 
role of CaM in altering VGSC function is one component of this dissertation and 
will be discussed later.   
D. Voltage-gated sodium channels in sensory neurons 
Neurons of the CNS exhibit relatively homogeneous currents 
characterized by rapid activation, rapid inactivation, and high sensitivity to TTX.  
In contrast, neurons of the DRG express more complex currents that contain 
both rapid-inactivating TTX-sensitive (TTX-S) components and slowly-
inactivating TTX-resistant (TTX-R) components (Kostyuk et al., 1981).  It was 
proposed the slower TTX-R currents might serve to prolong the duration of the 
action potential, possibly modulating neurotransmitter release at the nerve 
terminals.  TTX-S sodium currents in most, if not all, neurons exhibit multiple 
kinetic components.  Persistent or non-inactivating sodium current components 
have been identified in CNS neurons (Crill, 1996) and in DRG neurons (Baker 
and Bostock, 1997; Cummins and Waxman, 1997) and these currents can have 
significant influences on the threshold for generation of the action potential.  
However it was not until the advances in molecular biology and protein chemistry 
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of the late 1980s that the identification and cloning of individual sodium channel 
isoforms as well as the full complexity of VGSC and sodium currents could be 
adequately investigated.  
Alterations in sodium currents within the PNS can contribute to changes in 
cellular excitability and are likely to play important roles in nociception.  As 
mentioned earlier, adult sensory neurons can express TTX-S (Nav1.1, Nav1.6 
and Nav1.7) and TTX-R (Nav1.8 and Nav1.9) sodium channels.  These channels 
are critical in producing the all-or-none depolarization that is typical of action 
potentials in nociceptive (pain-sensing) neurons, and understanding their 
pharmacologic properties is important for the development of pain therapeutics.  
It has been suggested the TTX-sensitive (TTX-S) channels are responsible for 
the initiation of action potentials in both myelinated and unmyelinated axons 
(Brock et al., 1998; Ritter and Mendell, 1992).  These channels also have 
important roles in resting membrane potential and subthreshold oscillations.  The 
difference in TTX sensitivity has been very useful in characterizing TTX-R 
currents in DRG neurons; however, no pharmacological tools to date are 
effective at discriminating the different TTX-S neuronal isoforms. 
There have been several indications that changes in VGSC expression 
and/or modulation play a role in hyperexcitable states of neurons including 
inflammation, neuropathic pain, and nerve injury.  Changing the gating properties 
of VGSCs and/or the expression of VGSCs in the membranes of nociceptive 
neurons could increase excitability of these neurons thus producing pain.  The 
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inflammatory mediator prostaglandin E2 (PGE2) increased TTX-R current in 
sensory neurons and enhanced the voltage-dependence of activation for the 
current (Gold et al., 1996; England et al., 1996).  A recent study has revealed 
that nerve growth factor (NGF), a neurotrophin elevated in inflammatory exudates 
(Weskamp and Otten, 1987), and one of its downstream signaling molecules, 
ceramide, enhance the excitability of DRG neurons in culture by enhancing TTX-
R current (Zhang et al., 2002).  In contrast, it has been shown that mice lacking a 
functional form of the TTX-R Nav1.8 channel did not differ in its maximum level of 
hyperalgesia produced from inflammation (Akopian et al., 1999).  These mice 
lacking Nav1.8 did show increased levels of TTX-S currents and lower thresholds 
of electrical activation of small-diameter neurons.  Other work has shown 
increased TTX-S current amplitude in DRGs of rats that have developed 
hyperalgesia and allodynia in response to an induced diabetic state (Hong et al., 
2004).  A downregulation of TTX-R current and an upregulation of rapidly 
repriming TTX-S current have been observed in axotomized rat spinal sensory 
neurons (Cummins and Waxman, 1997).  Even with the findings of these studies, 
there still is little known about modulation of TTX-S channels that could underlie 
changes in nociception.  However, there is now compelling evidence the TTX-S 
VGSC subtype Nav1.7 (PN1) plays a critical role in nociception.  To date, the 
modulation and pharmacology of the Nav1.7 channel is not well characterized. 
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E. Characteristics of the Nav1.7 channel subtype 
The Nav1.7 isoform was originally cloned and studied from human 
neuroendocrine cells and was believed to be an evolutionary link between 
channels from brain and skeletal muscle (Klugbauer et al., 1995).  It was later 
observed the TTX-S Nav1.7 channel is expressed specifically at high levels in 
neuronal populations throughout the peripheral nervous system and exhibits 
features that distinguish it from Nav1.1, 1.2, and 1.3 channels (Toledo-Aral et al., 
1997).  The significant differences found from this study included some putative 
extracellular loops between S5 and SS1, the intracellular loop between domain I 
and II, and the carboxyl terminus.  Nav1.7 is expressed at high levels in rat and 
human dorsal root ganglia (DRG) and sympathetic ganglia (Black et al., 1996; 
Toledo-Aral et al., 1997; Sangameswaran et al., 1997) and responds to small, 
slow depolarizations thereby contributing to action potential generation.  Nav1.7 
is known to be expressed abundantly in nociceptive neurons from in vivo studies 
using guinea-pigs showing that Nav1.7-like immunoreactivity was greatest in cells 
with C-fiber axons (Djouhri et al., 2003).  Nav1.7 currents exhibit rapid activation 
and rapid inactivation from the open configuration (Klugbauer et al., 1995), 
similar to other TTX-S channels such as Nav1.4 and Nav1.6.  However in contrast 
to Nav1.4 and Nav1.6, which exhibit rapid recovery from fast inactivation, Nav1.7 
channels exhibit substantially slower recovery from fast inactivation (Cummins et 
al., 1998; Herzog et al., 2003a).  Biophysical properties of sodium currents 
generated by recombinant human Nav1.7 channels closely resemble those of the 
 12
predominant TTX-S current expressed in small diameter neurons of the DRG 
(Cummins et al., 1998). 
Although sodium channels are subject to extensive modulation, little is 
known about modulation of Nav1.7.  It has been reported recently that currents of 
Nav1.7 expressed in Xenopus oocytes are decreased by protein kinase A (PKA) 
and protein kinase C (PKC) (Vijayaragavan et al., 2004).  In contrast, activators 
of PKA had little effect on TTX-S currents of small diameter sensory neurons 
(Gold et al., 1996).  In addition, endothelin 1, an activator of PKC, showed no 
effects on TTX-S currents in large diameter sensory neurons (Zhou et al., 2002).  
However, the direct effects of PKA and PKC on Nav1.7 in sensory neurons have 
not been researched.  Another intracellular signaling protein, CaM, can bind to 
and alter the activity of VGSCs (Deschenes et al., 2002; Tan et al., 2002).  CaM, 
a 16.7 kDa protein is expressed in virtually all eukaryotic cells and has the ability 
to bind calcium ions and induce changes in target proteins.  It has been shown 
CaM can modulate Nav1.4 (skeletal muscle) and Nav1.6 (neuronal) current 
amplitudes and properties (Herzog et al., 2003b).  The C-terminus of Nav1.7 
binds CaM, although it has a lower apparent affinity than the C-termini of other 
TTX-sensitive isoforms.  Trifluoperazine (TFP) is one of the most potent CaM 
inhibitors among the phenothiazine neuroleptics (Brostrom and Wolff, 1981; 
Levin and Weiss, 1979).  Previous research has demonstrated intrathecal 
administration of TFP has analgesic effects at low doses (Golbidi et al., 2002).  
However, it is not clear how TFP is able to induce analgesia.  TFP reduces peak 
sodium current in a concentration-dependent manner in squid giant axons 
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(Ichikawa et al., 1991).  These studies raised the possibility TFP exerts its 
analgesic effects by modulating sodium currents in mammalian neurons and this 
might involve disruption of the CaM-channel interaction.  However, it is not 
known if CaM, or CaM antagonists, can modulate Nav1.7 currents. 
The first goal of this dissertation was to investigate if TFP can modulate 
Nav1.7 current and if this modulation was due to inhibition of the channel 
interaction with CaM.  As previous results indicated Nav1.7 had a lower affinity for 
CaM than Nav1.4 channels (Herzog et al., 2003b), and if TFP modulates Nav1.7 
current by altering the interaction with CaM, then TFP would have dissimilar 
effects on Nav1.4 and Nav1.7.  Examining the effects of TFP on Nav1.7 could 
lead to a better understanding the drug’s analgesic properties and possible use 
in regional anesthesia and thus pain management.  Therefore, in order to 
understand the potential impact of these findings, it is important to elaborate on 
the importance of Nav1.7 and its role in pain. 
F. Nav1.7 channels and pain 
Recent studies (Cox et al., 2006; Goldberg et al., 2007) indicate Nav1.7 
plays a crucial role in our ability to perceive pain. Cox et al. studied several 
families from Northern Pakistan that contained members with an inability to 
experience pain.  Neurological examinations indicated these individuals, age 6 to 
12 years old, apparently had never experienced any pain sensations while 
otherwise appearing normal.  The individuals were reported to have a profound, 
and apparently selective, inability to sense pain.  It was determined the condition 
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was congenital and could be mapped as an autosomal-recessive trait linked to a 
region of chromosome 2 containing the gene SCN9A, which encodes for the 
Nav1.7 channel.  Sequence analysis of SCN9A found several distinct 
homozygous nonsense mutations in the affected individuals of each of the three 
families.  In experiments using mutated recombinant Nav1.7 channels it was 
demonstrated each of the mutations identified in the three different families 
eliminated functional Nav1.7 currents in heterologous expression systems.  
Family members heterozygous for the SCN9A mutations, who therefore should 
have one functional SCN9A allele, reported normal pain phenotypes.  A separate 
study (Goldberg et al., 2007) identified Nav1.7 truncating mutations in patients 
with congenital indifference to pain from seven different countries, demonstrating 
loss-of-function of Nav1.7 can result in an insensitivity to pain in multiple 
populations.  As individuals lacking functional Nav1.7 channels appear normal 
except for their complete insensitivity to pain, drugs that selectively target Nav1.7 
might be ideal analgesics.  
Further support for the role of Nav1.7 in pain includes deletion of the 
mouse Nav1.7 gene in a subset of sensory neurons that are predominantly 
nociceptive creates decreased responses to noxious mechanostimulation and 
induced inflammatory pain (Nassar et al., 2004).  Recently, a recombinant herpes 
simplex-based virus was designed to knockdown expression of the Nav1.7 
channel.  When applied to the hindpaw skin of mice prior to induction of 
inflammation by with complete Freund’s adjuvant, this virus prevented 
development of hyperalgesia in thermonociceptive tests (Yeomans et al., 2005). 
 15
Interestingly, mutations in the Nav1.7 channel have been implicated in 
primary hereditary erythromelalgia (Yang et al., 2004; Drenth et al., 2005).  
Primary hereditary erythromelalgia is an inherited autosomal dominant painful 
neuropathy that is marked by intense burning pain and redness of the extremities 
and face (Van Genderen et al., 1993).  Electrophysiological studies on Nav1.7 
with the I848T, L858H, or L858F mutation implicated in hereditary 
erythromelalgia have shown hyperpolarized voltage-dependence of activation, 
slower deactivation kinetics, and larger ramp currents (Cummins et al., 2004; 
Han et al., 2006).  The L858H mutation is known to make DRG neurons 
hyperexcitable, while making sympathetic ganglion neurons hypoexcitable (Rush 
et al., 2006).  DRG neurons transfected with several other Nav1.7 mutations 
implicated in hereditary erythromelalgia (F1449V, A863P) have a lower threshold 
for firing action potentials and fire at higher-than-normal frequencies in response 
to suprathreshold stimulation (Dib-Hajj et al., 2005; Harty et al., 2006) which 
suggests these Nav1.7 mutations increase excitability of sensory neurons.  
Interestingly, erythromelalgia is not the only neuropathy implicated by mutations 
in Nav1.7.  A recent study has shown that a family affected by paroxysmal 
extreme pain disorder (PEPD), characterized by rectal, ocular, and 
submandibular pain, also have missense mutations in the SCN9A gene encoding 
for Nav1.7 (Fertleman et al., 2006).  Taken together, these studies indicate that 
changes in Nav1.7 properties play a crucial role in the production of pain and 
suggest that hereditary erythromelalgia mutations could serve as a model for 
examining changes in voltage-gated sodium channels that may contribute to pain 
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in humans.  Furthermore, these studies indicate changes in Nav1.7 properties 
play a role in the production of pain and understanding Nav1.7 biophysical and 
pharmacological properties is crucial for the advancement of pain therapeutic 
design.   
G. Interaction of voltage-gated sodium channels with local anesthetics 
Voltage-gated sodium channels are the primary target of local anesthetics 
(LAs) such as lidocaine (Taylor, 1959; Hille, 1966; Hille, 1977).  The main use of 
LAs is to prevent or relieve pain by reversibly preventing action potential 
propagation through the inhibition of VGSCs.  One problem with LAs is that they 
interact with most VGSCs in the body.  This non-selectivity of LAs is cause for 
concern in regards to unwanted side effects.  Since VGSCs reside in cardiac and 
muscle tissue, it is predictable LAs can cause a decreased activity of the heart, 
bowel, and skeletal muscle.  In fact, the LA lidocaine can be administered 
intravenously to patients as short-term management of ventricular arrhythmias.  
Thus, establishing a detailed pharmacologic and molecular basis for the complex 
interaction of LAs with the different VGSC subtypes throughout the body remains 
an important goal.   
A common theory for the dynamic and complex interaction between LAs 
and VGSCs has been termed the modulated receptor hypothesis (Hille, 1977).  
The modulated receptor hypothesis states that 1) affinity of a channel for LAs 
changes with channel state while access to the channel remains constant, 2) LAs 
can bind to any channel state, 3) LA bound states are non-conducting until LA 
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unbinds from the channel, 4) binding of LAs to the channel obeys first-order 
reaction kinetics, and 5) unbinding of LAs from the channel obeys zero-order 
kinetics.  Further investigation led to the discovery that LA inhibition of VGSCs is 
dependent on voltage and frequency of activation (Strichartz, 1973; Courtney, 
1975; Khodorov et al., 1976; Hille, 1977; Schwarz et al., 1977).  Another model 
for interaction of LAs with VGSCs has been termed the guarded receptor 
hypothesis (Starmer et al., 1984; Starmer and Grant, 1985).  In this model, the 
site of LA interaction with VGSC is “guarded” when the channel is in the closed 
or inactivated state.  Only when the channel opens does the binding site become 
“unguarded” by channel configuration allowing LAs to effectively interact with the 
channel.  
To date, the interaction of local anesthetics with the individual gating 
configurations of VGSCs remains controversial.  LAs are thought to interact with 
residues in the middle of the S6 transmembrane segments within domains I, III, 
and IV in the α-subunit of VGSCs (Ragsdale et al., 1994; Wang et al., 2000; 
Yarov-Yarovoy et al., 2002; Yarov-Yarovoy et al., 2001; Wright et al., 1998).  The 
S6 segments as mentioned earlier are thought to be arranged as α-helices that 
line the inner (cytoplasmic) portion of the pore in VGSCs (Fozzard and Hanck, 
1996; Catterall, 2000; Marban et al., 1998).  Point mutations of residues located 
in the S6 transmembrane segments can reduce high affinity binding of LAs to the 
inactivated state of the channel (Ragsdale et al., 1994; Wright et al., 1998; Li et 
al., 1999; Nau et al., 1999; Nau et al., 2003).  These results have provided further 
evidence as to the potential molecular site within VGSCs at which LAs interact.  
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However, the accessibility and configuration of these sites continue to be 
explored.   
One study done in squid giant axon showed that elimination of the fast 
inactivation mechanism after intracellular pronase treatment did not completely 
eliminate time- and voltage-dependent inhibition of Na+ current by LAs (Cahalan, 
1978).  However, in this same study, and in an additional study (Yeh, 1978), 
voltage-dependent and use-dependent inhibitory effects of QX-314, a quaternary 
ammonium derivative of lidocaine, on Na+ currents were eliminated meaning the 
fast inactivation mechanism of VGSCs important for QX-314 interaction with the 
channels.  In addition, other studies in the human cardiac VGSC showed that 
elimination of fast inactivation by mutation also reduced lidocaine induced use-
dependent inhibition (Bennett et al., 1995).  These studies provide evidence the 
fast inactivation component of Na+ channels play a role in use-dependent 
lidocaine inhibition.  Experiments using cardiac and skeletal muscle VGSCs in 
tissue or heterologous expression systems indicated the open-state of channel 
was not important for lidocaine interaction (Bean et al., 1983; Bennett et al., 
1995; Balser et al., 1996a) but in fact lidocaine served to enhance VGSC 
inactivation.  This idea was supported by a study showing that in rat Nav1.4 
channels, lidocaine increased the closure of the fast inactivation gate but did not 
cause the accumulation of fast-inactivated channels during use-dependent block 
(Vedantham and Cannon, 1999).  In other words, lidocaine does not trap the rat 
Nav1.4 channel into a fast-inactivated conformation.   
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Other theories in regard to LA interaction with VGSCs involve interaction 
of LAs with the slow-inactivated state of the channel.  One study done in 
Xenopus oocytes suggested lidocaine block on rat Nav1.4 channels was similar 
for fast-inactivated and slow-inactivated states of the channel (Balser et al., 
1996b).  Other studies done in rat Nav1.4 channels proposed that lidocaine 
interaction with the channel induced a transition to a slow-inactivated state (Chen 
et al., 2000; Fukuda et al., 2005).  Additional findings suggest use-dependent 
block of lidocaine creates a configuration of rat Nav1.4 channels similar to the 
slow-inactivated state (Ong et al., 2006).  These hypotheses propose slow 
inactivation in VGSCs is important in lidocaine block of the channel.  However, 
data from this dissertation conflict with these hypotheses.   
Opposing viewpoints support the idea that channel activation is critical in 
high affinity lidocaine interaction with VGSCs.  A study using squid giant axon 
showed that lidocaine competes for a similar site to which the fast inactivation 
gate may interact (Yeh and Oxford, 1985).  Not long after this discovery, it was 
discovered that eliminating Na+ channel inactivation in squid giant axon using 
chloramine-T had no effect on the potency of QX-314 and that channel activation 
was critical for interaction of LA with the channel (Wang et al., 1987).  A 
supporting study demonstrated LAs interact with inactivation-deficient rat Nav1.4 
channels expressed in HEK293 cells (Wang et al., 2004b).  Hanck et al. (2000) 
indicated lidocaine modified the S4 segments important in voltage-sensing of 
human Nav1.5 channels and have recently stated that the S4 segments of DIII 
and DIV are more important in this modification (Sheets and Hanck, 2007).  In 
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addition to these findings, it was concluded the fast inactivation gate was not 
necessary for lidocaine binding but is crucial for lidocaine to interact to the Nav1.5 
channel with high affinity (Sheets and Hanck, 2007).  These studies indicate the 
possibility that lidocaine interacts directly with the pore of VGSCs and becomes 
stabilized by the fast inactivation gate.   
Therefore, different mechanisms have been proposed regarding the state-
dependent block VGSCs by lidocaine.  However, to date the interaction of LAs 
with VGSCs is still not entirely understood and remains a matter of debate.  
Since lidocaine is used to prevent or relieve pain by reversibly blocking action 
potential propagation through the inhibition of VGSCs in sensory neurons and the 
Nav1.7 channel is highly implicated in pain production, then understanding the 
interaction of lidocaine with Nav1.7 becomes more important when considering 
lidocaine as a pain therapeutic.   
H. Nav1.7 and lidocaine 
To date there is very little information regarding the interaction of lidocaine 
with the Nav1.7 channel.  One study compared the effects of lidocaine on Nav1.7 
channels versus Nav1.8 channels in Xenopus oocytes (Chevrier et al., 2004).  
This study revealed Nav1.8 was more sensitive to lidocaine than Nav1.7 which 
was consistent with findings indicating TTX-R currents displayed more use-
dependent inhibition by lidocaine compared to TTX-S currents in DRG neurons 
(Roy and Narahashi, 1992).  However, this study also showed that TTX-S current 
was more sensitive to resting lidocaine block than TTX-R currents.  The 
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Cummins lab has also shown that TTX-R channels in DRG neurons are more 
sensitive to lidocaine than Nav1.7 channels expressed in a heterologous 
expression system (Sheets et al., 2007b).  It must be noted that this discrepancy 
in sensitivity was only observed at voltages where channels are resting/closed or 
completely inactivated.  Interestingly, when holding the channels at a potential 
close to or at threshold for firing (-50 mV), the differences in lidocaine inhibition 
between Nav1.7 and TTX-R channels is eliminated.  Chevrier et al. (2004) 
concluded that lidocaine enhances entry into the slow-inactivated state for Nav1.7 
and Nav1.8 channels.  This conclusion was investigated in this dissertation and 
the data obtained argue against it.   
 
I. Hypothesis and specific aims 
Previous research demonstrated that intrathecal administration of 
trifluoperazine (TFP) has analgesic effects at low doses (Golbidi et al., 2002).  
However, it is not clear how TFP is able to induce analgesia.  TFP is one of the 
most potent CaM inhibitors among the phenothiazine neuroleptics (Brostrom and 
Wolff, 1981; Levin and Weiss, 1979).  Several studies indicate CaM can bind to 
and alter the activity of voltage-gated sodium channels (Deschenes et al., 2002; 
Tan et al., 2002), and it was previously shown CaM can modulate Nav1.4 
(skeletal muscle) and Nav1.6 (neuronal) current amplitudes and properties 
(Herzog et al., 2003b).  TFP is also able to reduce peak sodium current in a 
concentration-dependent manner in squid giant axons (Ichikawa, et al., 1991).  
This raised the possibility TFP could exert its analgesic effects by modulating 
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sodium currents in mammalian neurons by disrupting the CaM-sodium channel 
interaction.  Therefore, it was hypothesized TFP can alter the 
electrophysiological properties of the Nav1.7 channel by disrupting the CaM-
channel interaction.  
Therefore, the first aim of this dissertation was to investigate if TFP can 
modulate Nav1.7 current and if this modulation was due to inhibition of the 
channel interaction with CaM.  Due to previous results indicating Nav1.7 channels 
have a lower affinity for CaM than Nav1.4 channels (Herzog et al., 2003b), it was 
predicted if TFP could modulate Nav1.7 current by altering the interaction with 
CaM, then TFP would have dissimilar effects on Nav1.4 and Nav1.7.  
Understanding the effects of TFP on Nav1.7 could lead to a better understanding 
of the drug’s analgesic properties, possible use in regional anesthesia, and pain 
management. 
Interestingly, a mutant Nav1.4 channel (N434K) used in the first specific 
aim of this dissertation stimulated the idea for the second specific aim of this 
dissertation.  Lysine substitution at this residue (N434K) in the rat Nav1.4 sodium 
channel reduces local anesthetic block of channel current (Nau et al., 1999).  
One mutation in primary hereditary erythromelalgia that has been associated with 
a severe phenotype is the N395K Nav1.7 mutation (Drenth et al., 2005), located 
in the S6 segment of domain I.  This N395 residue in Nav1.7 corresponds to 
N434 in the rat Nav1.4 sodium channel.  Unfortunately both of the affected 
individuals in the original family with the N395K mutation (Drenth et al., 2005) are 
now deceased and data on sensitivity of these patients to local anesthetics 
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cannot be attained.  However, a recent study showed treatment of 
erythromelalgia with lidocaine relieves pain in only 55% of afflicted patients 
(Davis and Sandroni, 2005).  Due to the multiple mutations involved in hereditary 
erythromelalgia, it may be possible some but not all of these mutations alter local 
anesthetic binding to Nav1.7, and this may contribute to the variability in patients 
responding to lidocaine.  Thus, it was hypothesized the N395K mutation in 
Nav1.7 would alter interaction of lidocaine with the channel whereas another 
erythromelalgia mutation (F216S) not in the local anesthetic binding site would 
not change this interaction.  Therefore, the second aim of this dissertation was to 
1) examine electrophysiological changes in Nav1.7 produced by the N395K 
mutation and 2) determine if the N395K mutation or F216S mutation in Nav1.7 
changes the effects of lidocaine on sodium channel current. 
 Results from the second aim showed that a two-site binding model gave a 
much better fit to the concentration-response curve for lidocaine inhibition of 
Nav1.7 channel current.  This fit indicated two possible lidocaine interaction 
configurations of Nav1.7, one exhibiting high affinity lidocaine binding and 
another exhibiting low affinity binding.  Therefore, the final hypothesis for this 
dissertation was that the high affinity and low affinity populations represent 
channels in different inactivated conformations.  Based on this hypothesis, the 
aims for the final part of this dissertation were to 1) determine how different 
inactivated conformations of Nav1.7 affect lidocaine inhibition on the channel and 
2) use PEPD mutations (I1461T and T1464I) that alter transitions between the 
different inactivated configurations of Nav1.7 to determine how these alterations 
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affect lidocaine’s ability to inhibit channel current.  Together, these findings will 
begin to answer questions about the complex interaction of lidocaine with the 
Nav1.7 channel.  
 Overall, this dissertation answers important questions regarding the 
pharmacology and biophysics of the understudied neuronal VGSC subtype, 
Nav1.7.  The recent evidence indicating Nav1.7 as a critical factor of pain in 
humans (Drenth et al., 2005; Michiels et al., 2005; Cox et al., 2006; Fertleman et 
al., 2006; Goldberg et al., 2007) makes researching this channel important in the 
advancement to more efficient pain therapy.  
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II. MATERIALS AND METHODS 
A. cDNA vectors 
The voltage-gated sodium channel subtype human Nav1.7 was previously 
cloned and constructed into a modified pcDNA 3.1 (-) vector (Klugbauer et al., 
1995).  This vector was used for all transfections and mutagenesis of the Nav1.7 
channel. The human Nav1.4 subtype was previously cloned (George Jr. et al., 
1992) and constructed into the expression vector pRc/CMV (Wang et al., 1996).  
This vector was used to produce the HEK293 cell line that stably expressed the 
Nav1.4 channel.  The rat Nav1.4 cDNA (Trimmer et al., 1989) had been 
previously cloned into a RBG4 vector (Ukomadu et al., 1992) and was 
characterized in HEK293 cells (Ukomadu et al., 1992; Cummins et al., 1993).  
This vector was used in transient transfections of the rat Nav.1.4 channel.  The 
rat Nav1.4 mutant channels were generous gifts from laboratory of Dr. Ging Kuo 
Wang.  The mutagenesis was originally done on the rNav1.4-pcDNA/amp to 
create N434K (Nau et al., 1999), L1280K (Wang et al., 2000), and F1579K 
(Wright et al., 1998) mutant channels.   
The vectors for the human β1 and β2 subunits were pCD8-IRES-hβ1 and 
pEGFP-IRES-hβ2 (CD8: cluster of differentiation 8, IRES: internal ribosome entry 
site, EGFP: enhanced green fluorescent protein) and have been used in previous 
studies (Lossin et al., 2002; Lossin et al., 2003).  Vectors containing an IRES 
allow for the production of two proteins from the same mRNA sequence.  Thus, 
in a mammalian expression system, the pCD8-IRES-hβ1 vector will produce CD8 
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and the human β1 protein, while the pEGFP-IRES-hβ2 vector will produce EGFP 
and the human β2 protein.  CD8 and EGFP are used as markers to confirm 
expression of the human β1 protein and human β2 protein, respectively.  In this 
dissertation, human β2 protein expression was confirmed by the presence of 
EGFP fluorescence in HEK293 cells.  Human β1 protein expression was 
assumed to correlate with human β2 protein expression and was not tested in 
experiments performed for this dissertation.  However, other experiments from 
this laboratory (done by Andrew D. Piekarz) show that cotransfection of the 
pCD8-IRES-hβ1 vector and the pEGFP-IRES-hβ2 vector in HEK293 cells produce 
expression of the human β1 protein in approximately 89% of cells expressing the 
human β2 protein.  These experiments were done by testing for the presence of 
CD8 in EGFP positive cells using Dynabeads (Dynal®, Brown Deer, WI, U.S.A.) 
which interact with the CD8 protein being expressed extracellularly.  
B. Mutagenesis of voltage-gated sodium channels 
Site directed mutagenesis of Nav1.7 was performed with the Nav1.7-
pcDNA 3.1 (-) vector by means of the QuikChange® II XL Site-Directed 
Mutagenesis Kit (Stratgene, La Jolla, CA, U.S.A.).  Mutagenic primers containing 
the desired mutation were designed to anneal to the same sequence on opposite 
strands of the plasmid.  The potential mutants were identified by restriction 
enzyme digestion and confirmed by DNA sequencing with appropriate primers 
near the mutated region of the plasmid.  DNA sequencing was performed at the 
DNA Sequencing Core Facility in the Biochemistry Biotechnology Facility of 
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Indiana University (Indianapolis, IN, U.S.A.).  Site directed mutagenesis of rat 
Nav1.4 was previously performed (Wang and Wang, 1997; Nau et al., 1999) with 
the Nav1.4-pcDNA1/amp vector using the Transformer Site-Directed Mutagensis 
Kit (Clonetech Inc., Palo Alto, CA, U.S.A.).     
C. Transfection and preparation of stably transfected cell lines 
Experiments investigating the effects of TFP on human Nav1.7 and Nav1.4 
channels were done using stably transfected cell lines.  To obtain these cell lines,  
human embryonic kidney cells (HEK293 cells; American Type Culture Collection; 
Manassas, VA, U.S.A.) were grown under standard tissue culture conditions (5% 
CO2; 37 oC) in Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, Grand 
Island, NY, U.S.A.) supplemented with 10% fetal bovine serum (FBS; Cellgro, 
Herndon, VA, U.S.A.) and 1% penicillin/streptomycin (Invitrogen, Grand Island, 
NY, U.S.A.).  Transfections of Nav1.4 and Nav1.7 cDNA were performed using 
the calcium phosphate precipitation technique.  No human β subunits were 
transfected with the channels as previous studies have shown β subunits do not 
alter the effect of CaM on sodium currents in HEK293 cells (Deschênes et al., 
2002; Young and Caldwell, 2005).  In addition, it has been demonstrated addition 
of human β1 and human β2 subunits had no effect on Nav1.3 voltage-dependent 
properties in HEK293 cells (Cummins et al., 2001).  For these experiments the 
calcium phosphate precipitation technique consisted of adding the following 
solutions together: 
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Solution 1 Solution 2 
40 µl 2X HEPES buffer 2.75—3 µg channel cDNA (at 1 µg/µl 
concentration)  
 5 µl 2M CaCl2
 sterile water (bring volume to 40 µl) 
 
Solution 2 was added to Solution 1 dropwise and was gently mixed and bubbled 
using a 100 µl pipettor. The calcium phosphate-DNA mixture was incubated at 
room temperature for 30 minutes after which time it was added to naïve HEK293 
cells contained within serum-free DMEM on a 100 x 20 mm culture dish.  After 
15-20 hours of incubation at 37 oC, the cells were washed with fresh complete 
DMEM medium (10% FBS, 1% pen/strep).  The Nav1.7 and Nav1.4 cDNA had 
been cloned in the pcDNA 3.1 (-) vector which contains the neomycin (G418) 
resistant gene for selection of stable cell lines using G418.  Therefore, after 48 
hours, antibiotic (G418, Geneticin®; Cellgro, Herndon, VA) was added to select 
for neomycin-resistant cells.  After 2-3 weeks in G418, HEK293 cell colonies 
resistant to G418 grew and were picked, allowed to grow on 12 mm glass 
coverslips (Microscope Cover Glass; Fisherbrand®, Pittsburgh, PA, U.S.A.) 
previously coated in laminin and subsequently tested for Nav1.7 or Nav1.4 
channel expression using whole-cell patch-clamp recording techniques 
(discussed later).  Cells producing more than 1 nA of sodium current were used 
for subsequent experiments.   
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D. Transient transfection of HEK293 cells 
Transient transfections were used for all experiments excluding those 
investigating the effects of TFP on human Nav1.7 and Nav1.4 channels.  For 
transient transfections, HEK293 cells were grown under standard tissue culture 
conditions (5% CO2; 37 oC) in DMEM supplemented with 10% fetal bovine serum 
and 1% penicillin/streptomycin.  Transfections of rat wild-type Nav1.4, rat mutant 
Nav1.4 (N434K, L1280K, F1579K), human wild-type Nav1.7, and human mutant 
Nav1.7 (N395K, F216S, I1461T, T1464I) were performed using the calcium 
phosphate precipitation technique explained above.  However, for transient 
transfections, the calcium phosphate-DNA mixture was added to naïve HEK293 
cells contained within DMEM supplemented with 5% fetal bovine serum and 1% 
penicillin/streptomycin on a 100 x 20 mm culture dish 1 minute after combining 
solution 1 and solution 2.  The mixture was left on the cells in culture for 3-6 hr, 
after which time the cells were washed with fresh DMEM supplemented with 10% 
fetal bovine serum.  For experiments involving transient transfections of wild-
type, N395K, I1461T, and T1464I Nav1.7 channels, human β1 and β2 subunits 
were cotransfected to enhance expression of the channel in HEK293 cells.  
When the human β1 and β2 subunits were included in the transfection, 0.4 µg of 
each subunit was included in Solution 2.   
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E. Chemicals 
For application during voltage-clamp experiments, trifluoperazine (TFP, 
Sigma Aldrich Co., St. Louis, MO) was dissolved in sterile water to give stock 
solutions of 10 mM and 300 μM, respectively.  Calmodulin inhibitory peptide 
(CIP, EMD Biosciences, Inc., San Diego, CA) was dissolved in sterile water to 
give a stock solution of 240 μM.  Lidocaine hydrochloride (Sigma Aldrich Co.) 
was dissolved in standard bathing solution to give a stock solution of 100 mM.  
Subsequent dilutions were performed in standard bathing solution to give 
concentrations of (in mM): 0.1, 0.3, 1, 3, 10, and 30.   
F. Solutions 
1. Standard bathing solution 
 The standard bathing solution was used to bath cells during all voltage-
clamp whole-cell electrophysiology experiments. The composition of the standard 
bathing solution was as follows (in mM): 140 NaCl, 1 MgCl2, 3 KCl, 1 CaCl2, and 
10 HEPES, pH 7.3 (adjusted with NaOH).  TFP was diluted in standard bathing 
solution before being externally applied to the stable HEK293 lines.  
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2.  Standard pipette solution 
 The standard pipette solution was used in all experiments except for those 
involving the use of the CIP.  The composition of the standard pipette solution 
was as follows (in mM): 140 CsF, 10 NaCl, 1.1 EGTA, and 10 HEPES, pH 7.3 
with CsOH.   
3. Pipette solution used for the CIP experiments 
 A different pipette solution was used when testing the effects of CIP on 
Nav1.7 or Nav1.4 channels.  Since the effectiveness of CIP to inhibit calmodulin is 
based on intracellular Ca2+ levels, a more effective Ca2+ chelator, BAPTA, to 
better control the level of intracellular Ca2+ when looking at the effects of CIP on 
channel properties was used.   The pipette solution used for the CIP experiments 
had the following composition (in mM): 90 CsF, 10 BAPTA, 10 NaCl, 10 HEPES, 
pH 7.3.  CsOH was used to adjust pH for the pipette solutions.  CIP was added to 
this solution when testing its effects on channel properties.   
G. Whole Cell Patch-Clamp Recordings 
 Whole cell patch-clamp recordings were conducted at room temperature 
(~21 oC) using a HEKA EPC-10 double amplifier.  Data were acquired on a 
Windows-based Pentium IV computer using the Pulse program (v 8.65, HEKA 
Electronic, Lambrecht/Pfalz, Germany).  Fire-polished electrodes (0.9—1.3 MΩ) 
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were fabricated from 1.7 mm VMR Scientific (West Chester, PA, U.S.A.) capillary 
glass using a Sutter P-97 puller (Novato, CA, USA).  For holding coverslips 
containing transfected HEK293 cells during whole cell patch-clamp recordings, 
lids from 35 mm cell culture dishes (Corning Inc.®, Corning, NY, U.S.A.) were 
filled with silicone elastomer base (Sylgard®, World Precision Instruments Inc., 
Sarasota, FL, U.S.A.), mixed with a curing agent, and allowed to solidify.  After 
solidification, a scalpel was used to cut around a single 12 mm coverslip into the 
silicone creating a reservoir that could hold a coverslip and approximately 300 µl 
of bath solution.   
 The recording dish containing transfected cells was mounted on an 
inverted Leitz Fluovert microscope equipped with a fluorescent light source and 
Hoffman modulated contrast objectives.  The microscope was on a vibration 
isolation table with a 2 inch stainless steel laminate (63-500 Series, Technical 
Manufacturing Company, Peabody, MA, U.S.A.) to counter all negative effects of 
vibration on the experiments.  All electrophysiological experiments were 
performed without the use of a Faraday cage.  However, multiple wires were 
used to ground all metal surfaces having the potential to serve as an antenna for 
aberrant electrical noise.  These wires converged at a single point on the air table 
from which a single wire was connected to the ground input of the amplifier.   
 Isolated cells for whole-cell electrophysiology were chosen by morphology 
and/or expression of EGFP.  A fresh electrode back-filled with the appropriate 
intracellular solution was used each time a new electrophysiological experiment 
was started.  Once filled with the appropriate intracellular solution, the recording 
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electrode had an approximate resistance of 1.0—1.2 MΩ.  The EPC10 amplifier’s 
offset potential was zeroed with the electrode almost touching the cell of interest.  
A silver chloride (AgCl) coated silver wire served as a reference electrode with 
one end connected to the ground input of the amplifier headstage and the AgCl 
coated end placed directly into the bath solution.  The liquid junction potential for 
all solutions was not corrected for during these experiments and data analysis.  
After obtaining a cell membrane-glass interaction creating over 1 GΩ resistance, 
suction was used to establish the whole-cell recording configuration.  Series 
resistance errors were compensated to be less than 3 mV and the capacitance 
artifact was canceled using computer-controlled circuitry of the patch-clamp 
amplifier.  Linear leak subtraction, based on resistance estimates from four to five 
hyperpolarizing pulses applied before the depolarizing test potential, was used for 
all voltage-clamp recordings.  Recordings were always started at least 3 min after 
establishing the whole-cell configuration.  Membrane currents were filtered at 5 
kHz and sampled at 20 kHz.  Cells having a leak current of more than 10% of the 
peak sodium current were discarded and not used for analysis.  Time-dependent 
shifts in current amplitude and voltage-dependence were calculated for all paired 
experiments.  Specific voltage protocols are described within the Results section 
of this dissertation.  When the perfusion system (described below) was not used, 
compounds were added to the bath compartment by first withdrawing 25 μl of 
bathing solution, then adding 25 μl of 10-fold concentrated compound and mixing 
10-15 times with a 25 μl pipettor. 
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1. Perfusion System 
 For obtaining lidocaine dose-response curves for inhibition of Nav1.7 
channel current in Figures 19 and 20, a SF-77B Perfusion Fast-Step system 
(Warner Instruments, LLC, Hamden, CT, U.S.A.) was used to deliver different 
concentrations of lidocaine focally onto the transfected HEK293 cell in whole cell 
configuration (Figure 3).  During these experiments, coverslips containing 
transfected HEK293 cells were placed into a RC-26 Open Diamond Bath 
perfusion chamber (Warner Instruments, LLC, Hamden, CT, U.S.A.) with a small 
amount of Vaseline.  This chamber allows a constant laminar flow of bath 
solution across the cells which was perfused at approximately 1 ml/min using 
gravity flow and removed using a Masterflex® C/L® Single Channel Variable- 
Speed peristaltic pump (Cole-Parmer Instrument Company, Vernon Hills, IL, 
U.S.A.).  The perfusion system was constructed using various sizes of 
polyethylene tubing (Warner Instruments, LLC, Hamden, CT, U.S.A.).  The drug 
delivery 3-barrel tube was placed near the transfected HEK293 cell, and its 
positioning was calibrated before each experiment.  The position of the drug 
delivery tube was controlled manually by a stepper motor which could change the 
positioning in about 20 milliseconds.  Concentrations of lidocaine were applied in 
random order and were allowed to interact with the cell 30 seconds prior to 
recording.  All solutions were kept at room temperature (~21 oC).  After 
experiments were completed for the day, all tubing was cleaned thoroughly with 
deionized water and, once a week, the tubing was cleaned with 70% ethanol.    
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Figure 3.  Schematic diagram of perfusion system used to obtain lidocaine 
dose response effects on Nav1.7 channels.  
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H.  Data Analysis 
 Voltage-clamp experimental data were analyzed using the Pulsefit (v 8.65, 
HEKA Electronic, Germany) and Origin (OriginLab Corp., Northhampton, MA, 
U.S.A.) software programs.  Slope factors of activation and steady-state 
inactivation curves were calculated using the general Boltzmann function: 
( ) ⎟⎠
⎞⎜⎝
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+= − kVVeII /max 5.01
1/  where I = measured current, Imax = maximum current, V = 
command voltage, V0.5 = voltage at which the normalized current value is 0.5, 
and k = slope factor describing the steepness of the relationship.  An offset value 
was added to the Boltzmann equation when fitting to some slow inactivation 
profiles to address incomplete inactivation.  The equation used for the one-site 
binding curve and two-site binding curves for dose-inhibition relationship for 
lidocaine and the Nav channels were as follows: 
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Parameters for exponential fitting are presented in the Results section of the 
dissertation.  The order (i.e. first-order, second-order) of exponential fit was 
chosen after an increase in the order of the fit produced an extra parameter that 
1) was less than 5% of the total fit and 2) produced an estimated tau value 
outside the range of the fit.  Goodness of fit was set at R2 > 0.90 for all fits.  
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Results are presented as mean ± S.E.M., and error bars in the figures represent 
SEs.  Statistical significance was set at p < 0.05 for all experiments.  
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III. RESULTS 
A.  Inhibition of Nav1.7 and Nav1.4 sodium channels by trifluoperazine (TFP) 
involves the local anesthetic interaction site 
1. TFP decreases currents produced by Nav1.7 and Nav1.4 channels 
To determine if TFP could affect mammalian voltage-gated sodium 
currents, TFP was applied externally to HEK293 cells stably-transfected with 
human Nav1.7 or human Nav1.4 channels, and sodium currents were monitored 
using whole-cell voltage clamp techniques.  Cells were held at -100 mV and 
pulsed to 0 mV every five seconds to elicit channel current.  In the presence of 
500 nM or 2 μM TFP, sodium currents rapidly declined and stabilized within 15 
seconds and 25 seconds for Nav1.7 and Nav1.4, respectively (Figure 4, A and C).  
Although a small hyperpolarizing shift in the current-voltage relationship for 
Nav1.7 and Nav1.4 was observed following application of 2 μM TFP (Figure 4, B 
and D), these shifts were not significantly different from the time-dependent shifts 
observed in control cells.  Nav1.7 showed decreases in peak sodium currents of 
19.4 ± 6.0 % (n = 6) and 76.7 ± 4.6 % (n = 6) after approximately 2.5 minutes 
during application of 500 nM and 2 μM TFP, respectively.  Under the same 
conditions the same two concentrations of TFP produced decreases in peak 
Nav1.4 currents of 14.7 ± 7.3 % (n = 6) and 59.4 ± 7.8 % (n = 5), respectively. 
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Figure 4.  Inhibition of current produced from Nav1.7 and Nav1.4 channels 
by TFP.  A and C, comparison of effects of two different TFP concentrations on 
currents produced by Nav1.7 (A) and Nav1.4 (C) channels.  Saline controls 
represent the change in sodium current after application of cold external bath 
solution.  The external bath solution was cold because TFP was kept cold in 
order to maintain its integrity.  Drug or cold external bath solution was added to 
the external bath solution approximately 45 seconds into the protocol.  B and D, 
effects of 2 µM TFP on the current-voltage relationship for Nav1.7 (B) and Nav1.4 
(D) channels.  The scaled group represents current values of the TFP treated 
channels normalized to the peak current of the control channels.  Data is 
presented as mean normalized sodium current ± S.E.M.   
 40
2. TFP causes hyperpolarizing shifts in the voltage-dependence of Nav1.7 
and Nav1.4 steady-state inactivation 
To understand how TFP reduces sodium current amplitude the effect of 
TFP on steady-state inactivation was investigated.  Application of 500 nM and 2 
μM TFP to cells expressing Nav1.7 caused hyperpolarizing shifts of -5.0 ± 0.87 
mV (n = 6) and -18.4 ± 2.3 mV (n = 6) in the V1/2 of steady-state inactivation, 
respectively (Figure 5, A and B), where V1/2 was determined by fitting the data 
with the standard Boltzmann function as described in the Methods.  The slope 
factor of the steady-state inactivation curve for Nav1.7 in the absence of TFP was 
6.6 ± 0.1 mV-1.  Following application of 500 nM and 2 μM TFP the slope factors 
were 7.0 ± 0.3 mV-1 and 10.2 ± 0.5 mV-1, respectively.  Application of the same 
two concentrations of TFP to cells containing Nav1.4 caused hyperpolarizing 
shifts in the V1/2 of steady-state inactivation of -5.0 ± 0.87 mV (n = 5) and -11.4 ± 
0.80 mV (n = 6), respectively (Figure 5, D and E).  The slope factor of the steady-
state inactivation curve for Nav1.4 in the absence of TFP was 6.0 ± 0.1 mV-1.  
Following application of 500 nM and 2 μM TFP the slope factors were 5.9 ± 0.1 
mV-1 and 6.6 ± 0.3 mV-1, respectively.  In control experiments (without TFP 
application) time-dependent shifts were observed in the V1/2 of steady-state 
inactivation taken 7 minutes apart for Nav1.7 channels (-2.6 ± 0.43 mV; n = 6) 
and Nav1.4 channels  (-4.7 ± 1.1 mV; n = 5).  Thus, application of 500 nM TFP 
did not cause a significant hyperpolarizing shift in the V1/2 of steady-state 
inactivation of Nav1.7 or Nav1.4 compared to the hyperpolarizing shift that was 
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Figure 5.  Shift in steady-state inactivation of Nav1.7 and Nav1.4 channels in 
the presence of TFP.  Cells containing the channels were held at -100 mV and 
stepped to an inactivating pre-pulse (-130 to 40 mV) for 500 ms.  The channels 
available after each inactivating pre-pulse were assessed by the peak current 
produced during a test pulse to -10 mV for 25 ms.  A and B, 500 nM (A) and 2 
μM TFP(B) caused hyperpolarizing shifts in steady-state inactivation curves of 
Nav1.7 channels.  The average value of V1/2 of inactivation for control conditions 
of Nav1.7 channels was -83.9 ± 1.5 mV which was averaged from experiments in 
A and B.  C, TFP and time caused hyperpolarizing shifts (mV) in V1/2 of 
inactivation for Nav1.7 channels.  TFP (2 μM) in the external bath solution was 
the only condition to cause a significant shift in V1/2 of inactivation compared to 
the time-dependent control.  D and E, 500 nM (D) and 2 μM TFP (E) caused 
hyperpolarizing shifts in steady-state inactivation curves of Nav1.4 channels.  The 
average value of V1/2 of inactivation under control conditions for Nav1.4 channels 
was -74.8 ± 2.0 mV which was averaged from experiments in D and E.  F, TFP 
and time also caused hyperpolarizing shifts (mV) in V1/2 of inactivation for Nav1.7 
channels.  Statistical significance was determined using a Student’s paired t test 
(* = p <0.05).  
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observed in these channels over the same period of time in control experiments.  
However, 2 μM TFP did cause a significant hyperpolarizing shift in the V1/2 of 
steady-state inactivation of Nav1.7 channels and Nav1.4 channels compared to 
time-dependent controls (Figure 5, C and F).  Mechanistically, changes in slope 
factors caused by TFP cannot be readily explained.   
3. TFP shows use-dependent inhibition of Nav1.7 and Nav1.4 during high 
frequency stimulation   
The hyperpolarizing shifts of steady-state inactivation of both Nav1.7 and 
Nav1.4 by 2 µM TFP indicates that TFP enhances sodium channel inactivation 
and led to the proposal that TFP might exhibit use-dependent inhibition of sodium 
channels.  This was investigated by pulsing the transfected cells to -10 mV at a 
frequency of 5 Hz in the absence and presence of drug.  Figure 6 (A and B) 
displays examples of results obtained under control conditions (left) and in the 
presence of 2 μM TFP (right) for both Nav1.7 and Nav1.4.  In the presence of 500 
nM TFP, there were 67.6 ± 3.3 % (n = 6) and 54.1 ± 6.7 % (n = 5) decreases in 
the current amplitudes evoked by the first pulse to the current amplitudes evoked 
by the last pulse in the protocol for Nav1.7 and Nav1.4, respectively. In the 
presence of 2 μM TFP, decreases of 73.8 ± 5.6 % (n = 6) and 80.4 ± 3.4 % (n = 
6) were observed for Nav1.7 and Nav1.4, respectively.  All decreases in peak 
current amplitudes were significant compared to time-dependent decreases in 
peak current amplitudes in the absence of drug (Figure 6, C and D). 
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Figure 6.  Use-dependent block of the Nav1.7 channels and Nav1.4 channels 
by TFP.  High frequency stimulation consisted of pulses from a holding potential 
of -100 mV to -10 mV at a frequency of 5 Hz to evoke sodium currents.  A (left), 
example of peak sodium currents produced by Nav1.7 channels during high 
frequency stimulation under control conditions.  A (right), peak currents from the 
same Nav1.7 channels during high frequency stimulation in the presence of 2 μM 
TFP.  B (left), example of peak sodium currents produced by Nav1.4 channels 
during high frequency stimulation under control conditions.  B (right), peak 
currents from the same Nav1.4 channels during high frequency stimulation in the 
presence of 2 μM TFP.  C and D, displays the decrease of peak sodium current 
produced by Nav1.7 channels (C) and Nav1.4 channels (D) from the first pulse to 
the last pulse of the high frequency stimulation protocol under control conditions 
compared to in the presence of drug.  Data are presented as mean % decrease 
in current between the 1st and 20th pulse ± S.E.M.  Statistical significance was 
determined using a Student’s paired t test (* = p < 0.05).   
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4. Steady-state inactivation is altered in Nav1.7 but not Nav1.4 in the    
presence of 1 μM calmodulin inhibitory peptide   
To determine if the mechanism by which TFP altered the currents 
conducted by Nav1.7 and Nav1.4 involved inhibition of the CaM-sodium channel 
interaction, currents were observed in the presence of a more specific CaM 
inhibitor.  For these experiments a CaM inhibitory peptide, a 17-residue peptide 
based on the CaM-binding domain of myosin light chain kinase that binds to CaM 
with a Kd of 6 pM (Torok, et al., 1998) was used.  The CaM inhibitory peptide is 
not cell permeable and had to be added directly to the pipette solution.  
Recordings were taken 12 minutes after obtaining whole-cell configuration to 
allow for adequate diffusion of the peptide into the cell.  For control experiments, 
no peptide was added to the pipette solution.  
Changes in steady-state inactivation of Nav1.7 were observed in the 
presence of 1 μM CaM inhibitory peptide (Figure 7A).  The mean V1/2 of steady-
state inactivation of Nav1.7 in the presence of 1 μM calmodulin inhibitory peptide 
was significantly hyperpolarized compared to without the peptide (Figure 7C).  In 
contrast, steady-state inactivation of Nav1.4 was unaffected by the presence of 1 
μM calmodulin inhibitory peptide (Figure 7B).  The mean V1/2 of inactivation of 
Nav1.4 in the presence and absence of the peptide were not statistically different 
(Figure 7C).  These results reveal specific inhibition of CaM had significant 
effects on Nav1.7 steady-state inactivation while having no effect on Nav1.4 
steady-state inactivation.   
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Figure 7.  Calmodulin inhibitory peptide affects steady-state inactivation in 
Nav1.7 channels but not Nav1.4 channels.  Cells containing the channels were 
held at -100 mV and stepped to an inactivating pre-pulse (-130 to 40 mV) for 200 
ms.  The channels that remain available after each inactivating pre-pulse were 
assessed by the peak current produced during a test pulse to -10 mV for 25 ms.  
A, Steady-state inactivation curves for Nav.1.7 current with (n = 5) and without (n 
= 5) 1 μM calmodulin inhibitory peptide.  B, Steady-state inactivation curves for 
Nav1.4 current with (n = 3) and without (n = 3) 1 μM calmodulin inhibitory peptide.  
C, 1 μM calmodulin inhibitory peptide causes a significant hyperpolarizing shift in 
the V1/2 of steady-state inactivation for the Nav1.7 channel.  1 μM calmodulin 
inhibitory peptide had no significant effects on the V1/2 of steady-state inactivation 
for the Nav1.4 channel.  Statistical significance was determined using a Student’s 
unpaired t test (* = p <0.05).  
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5. Calmodulin inhibitory peptide shows different effects on Nav1.7 and 
Nav1.4 during high frequency stimulation   
Calmodulin inhibitory peptide induction of use-dependent inhibition on 
voltage-gated sodium currents was also examined.  Figure 8, A and B, displays 
examples of the protocol results in the presence of 1 μM calmodulin inhibitory 
peptide for Nav1.7 and Nav1.4, respectively.  In cells recorded with 1 μM 
calmodulin inhibitory peptide added to the pipette solution the use-dependent 
decrease of  Nav1.4 current amplitudes was small (12.43 ± 1.69 %; n = 5), but 
significantly larger compared to the use-dependent decrease in cells recorded in 
pipette solution without the peptide (4.19 ± 0.19%; n = 5, Figure 7C).  Calmodulin 
inhibitory peptide (1 μM) in the pipette solution induced a small but significant 
use-dependent effect on currents produced by Nav1.7 stimulated at high 
frequency (Figure 8C).  Nav1.7 stimulated at high frequency with the pipette 
solution alone showed a 16.6 ± 5.1 % (n = 5) decrease in current.  This decrease 
was significantly smaller than the 32.4 ± 4.3 % (n = 5) decrease in current seen 
with 1 μM CaM inhibitory peptide in the pipette solution (Figure 8C).  The use-
dependent effects of the CaM inhibitory peptide on Nav1.7 and Nav1.4, although 
significant, were not as large as the effects seen with TFP.  This result, in 
conjunction with the observation the calmodulin inhibitory peptide had no effect 
on Nav1.4 steady-state inactivation, led to the hypothesis that the effects of TFP 
on these channels is the result of something other than blocking CaM-channel 
interactions.   
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Figure. 8.  Use-dependent block of Nav1.7 and Nav1.4 channels by 
calmodulin inhibitory peptide.  High frequency stimulation followed the same 
protocol as shown in Figure 4.  Since the calmodulin inhibitory peptide is not cell 
permeable it was added to the pipette solution.  Control conditions represent 
pipette solution without the peptide.  The high frequency stimulation protocol was 
performed 12 minutes after attaining whole-cell configuration.  A, example of 
peak sodium currents produced by Nav1.7 channels during high frequency 
stimulation in the presence of 1 μM calmodulin inhibitory peptide. B, example of 
peak sodium currents from Nav1.4 channels during high frequency stimulation in 
the presence of 1 μM calmodulin inhibitory peptide.  C, displays the decrease of 
peak sodium current produced by Nav1.7 channels and Nav1.4 channels from the 
first pulse to the last pulse of the high frequency stimulation protocol under 
control conditions compared to in the presence of the peptide.  Data are 
presented as mean % decrease in current between the 1st and 20th pulse ± 
S.E.M.  Statistical significance was determined using a Student’s unpaired t-test. 
(* = p < 0.05).   
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6.  TFP has a higher affinity for inactivated sodium channels than for 
resting channels   
 As local anesthetics (LA) exhibit use-dependent inhibition of sodium 
currents and induce a negative shift in the voltage-dependence of sodium 
channel steady-state inactivation, it was hypothesized TFP might be acting as a 
LA.  According to the modulated receptor hypothesis of LA inhibition of sodium 
channels, the affinity of the LAs for sodium channels depends on the state of the 
channel, with inactivated channels exhibiting much higher affinities than resting 
channels.  Therefore the ability of 2 μM TFP to block Nav1.7 and Nav1.4 channels 
in the resting state was tested using a holding potential of -140 mV.  Current was 
elicited with a pulse to 0 mV every 5 s and TFP caused an 8.3 ± 0.5 % (n = 10) 
and 8.4 ± 1.1% (n = 10) decrease in Nav1.7 and Nav1.4 current, respectively.  
This indicates that block of resting channels by TFP is similar for Nav1.7 and 
Nav1.4, with an estimated IC50 of ~22 µM.  To examine TFP effects on 
inactivated channels, cells were held at -120 mV and pre-pulsed to -60 mV for 10 
seconds, pulsed to -120 mV for 50 ms to allow for recovery from fast inactivation, 
and then pulsed to 0 mV to elicit current.  With this protocol, TFP caused an 85.6 
± 2.1 % (n = 5) and 87.4 ± 8.2% (n = 5) decrease in Nav1.7 and Nav1.4 current, 
respectively.  This indicates block of inactivated channels by TFP is also similar 
for Nav1.7 and Nav1.4, with an estimated IC50 of ~300 nM.  These data suggest 
that, like LA inhibition, TFP inhibition is dependent on the configuration or state of 
VGSCs (i.e. state-dependent).  Therefore, the disparity in block of Nav1.7 and 
Nav1.4 currents by 2 μM TFP observed in Figure 4 can be explained by 
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differences in steady-state availability rather than differences in channel affinities 
for TFP.   
7. TFP increases the onset of inhibition and slows recovery from 
inhibition for Nav1.7 and Nav1.4  
The effect of TFP on Nav1.7 and Nav1.4 currents was further investigated 
by examining the time course for onset of inhibition and recovery from inhibition 
for Nav1.7 and Nav1.4 currents.  Figure 9A (top) displays the protocol used to 
examine the onset of TFP inhibition for Nav1.7 and Nav1.4 currents.  In the 
absence of TFP, this protocol will display the onset of slow inactivation for Nav1.7 
and Nav1.4.  The onset of inhibition for Nav1.7 and Nav1.4 currents by 2 µM TFP 
was rapid compared to the development of slow inactivation observed under 
control conditions (Figure 9A bottom).  The time constants for the inhibition of 
Nav1.7 and Nav1.4 currents by 2 µM TFP were 49.1 ± 3.9 ms (n = 13) and 62.6 ± 
6.0 ms (n = 14), respectively and were not significantly different.  The onset of 
Nav1.7 and Nav1.4 current inhibition by 500 nM TFP was significantly slower than 
that observed with 2  µM TFP giving time constants of 148 ± 24 ms (n = 5) and 
139 ± 26 ms (n = 5), respectively.  Figure 9B displays the protocol used to 
examine the recovery from TFP inhibition for Nav1.7 and Nav1.4 currents.  TFP 
was present during this protocol; no washout was used.  The recovery of Nav1.7 
currents from inhibition by 500 nM and 2 µM TFP (Figure 9C, top) had
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Figure 9.  Onset of TFP 
inhibition and recovery from 
TFP inhibition for Nav1.7 and 
Nav1.4 channels.  A (top), 
protocol for examining onset of 
TFP-induced Nav1.7 and Nav1.4 
channel inhibition.  A (bottom), 
onset of 2 µM TFP inhibition for 
Nav1.7 and Nav1.4 channels.  
Decrease in Nav1.7 and Nav1.4 
current under control conditions is 
likely due to slow-inactivation.  B, 
protocol for examining recovery 
from TFP -induced Nav1.7 and 
Nav1.4 channel inhibition.  C 
(top), recovery from 500 nM and 2 
µM TFP inhibition for Nav1.7 
channels.  C (bottom), recovery 
from 500 nM and 2 µM TFP 
inhibition for Nav1.4 channels. 
 51
time constants of 572 ± 36 ms (n = 6) and 686 ± 43 ms (n = 9), respectively.  The 
recovery of Nav1.4 currents from inhibition by 500 nM and 2 µM TFP (Figure 9C, 
bottom) was slower with time constants of 1.0 ± 0.1 s (n = 5) and 1.2 ± 0.06 s (n 
= 10), respectively.  TFP concentration did not have a significant effect on the 
time constants of recovery for either Nav1.7 or Nav1.4.  This is consistent with the 
interaction seen between LAs and sodium channels in which drug unbinding rate 
was unrelated to drug concentration, indicating a simple bimolecular reaction of 
drug and channel (Bean et al., 1983).   
8. TFP showed attenuated effects on LA binding site mutations N434K 
and F1579K, but not L1280K   
To confirm that TFP was acting as a LA on Nav1.7 or Nav1.4, the effects of 
TFP were tested on Nav1.4 channels that have mutations in their LA binding site.  
LAs can directly bind to voltage-gated sodium channels and block the 
propagation of action potentials.  Previous studies have shown that point 
mutations of residues located in the S6 transmembrane segments of domain 1 
(DI), domain 3 (DIII), and domain 4 (DIV) of voltage-gated sodium channels can 
reduce high affinity binding of LAs to the inactivated state of the channel 
(Ragsdale, et al., 1994; Wright, et al., 1998; Li, et al., 1999; Nau, et al., 1999; 
Nau, et al., 2003).  Furthermore, it has been shown that the tricyclic 
antidepressant amitriptyline, which blocks voltage-gated sodium channels with a 
high degree of use-dependent block under repetitive pulses, also interacts with 
the LA binding site on sodium channels (Barber, et al., 1991; Nau, et al., 2000).  
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Three specific S6 residues located at DI, DIII, and DIV have been characterized 
as crucial for both LAs and amitriptyline binding in rat skeletal muscle (Nav1.4) 
sodium channels (Wang, et al., 2004).  Lysine and arginine substitutions at 
residues N434 (DI-S6), L1280 (DIII-S6), and F1579 (DIV-S6) reduced the affinity 
for both amitriptyline and LA binding to the inactivated state of the channel 
(Wang, et al., 2004; Nau and Wang, 2004).  In order to determine if TFP was 
acting through a possible LA mechanism, TFP was applied to rat Nav1.4 
channels having one of three amino acid substitutions (N434K, L1280K, F1579K) 
and the effectiveness of TFP inhibition was examined.   
Since these LA binding-site mutations were performed with rat Nav1.4, 
and the data shown in Figures 4-6 used human Nav1.4, the control conditions 
involved application of TFP to wild-type rat Nav1.4.  Rat and human Nav1.4 
channels are highly conserved, and completely conserved in the CaM and LA 
binding site regions.  Figure 10A displays the effects of application of 2 μM TFP 
to the external bath solution on sodium currents from the wild-type rat Nav1.4 and 
the LA binding site mutant channels.  The addition of 2 μM TFP to wild-type rat 
Nav1.4 caused a decrease in peak sodium current of 83.7 ± 2.6 % (n = 6; Figure 
10B).  Two of the LA binding site mutant channels, N434K and F1579K, showed 
a significant attenuation in the decrease of peak sodium current caused by 2 μM 
TFP to 12.5 ± 1.8 % (n = 5) and 7.01 ± 3.2 % (n = 5), respectively.  In contrast, 
the L1280K mutant channel showed a decrease of 80.3 ± 3.1 % (n = 5) in peak 
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Figure 10.  Effects of TFP on current produced from rat Nav1.4 channels 
and rat channels containing the mutations, N434K, L1280K, or F1579K in 
the LA binding site.  The protocols for A and B are described in the Figure 4 
legend.  A, 2 μM TFP caused decreases in current produced by the all channels 
having a reduced effect on the N434K and F1579K channels.  B, comparison of 
effects of 2 μM TFP on the rat Nav1.4 channels and rat LA mutant channels 
shows that the LA mutant channels, N434K and F1579K, displayed a significant 
reduction in % decrease of peak current.  The protocol for C is described in the 
Figure 5 legend.  C, shift in steady-state inactivation of rat Nav1.4 channels and 
rat LA mutant Nav1.4 channels, N434K, L1280K, F1579K in the presence of TFP.  
D, use-dependent block of the rat Nav1.4 channels and rat LA mutant Nav1.4 
channels, N434K, L1280K, F1579K in the presence of 500 nM or 2 μM TFP.  
High frequency stimulation followed the same protocol as shown in Figure 4.  
Statistical significance was determined using a one-way ANOVA analysis 
followed with a Tukey’s comparison test (* = p < 0.05).  Statistical comparisons 
were made against WT values.   
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sodium current which was not significantly different from the decrease observed 
with the wild-type channel (Figure 10B).  As seen with human Nav1.7 and Nav1.4, 
TFP caused a significant hyperpolarizing shift in the V1/2 of steady-state 
inactivation of rat Nav1.4.  Application of 2 μM TFP to rat Nav1.4 caused a 
hyperpolarizing shift of -14.8 ± 1.1 mV (n = 6; Figure 10C).  The N434K and 
F1579K mutant channels showed significantly smaller hyperpolarizing shifts in 
V1/2 of steady-state inactivation in the presence of 2 μM TFP, having only shifts of 
-6.5 ± 1.1 mV (n = 5) and -5.0 ± 0.5 mV (n = 5), respectively (Figure 10C).  The 
L1280K mutant channel in the presence of 2 μM TFP exhibited a hyperpolarizing 
shift of -14.6 ± 2.6 mV (n = 5; Figure 10C), which was not significantly different 
than that seen with the wild-type channel.   
 Use-dependent effects of TFP were also studied with the rat Nav1.4 as 
well as with the LA binding-site mutant channels by using the same 5 Hz pulse 
protocol that was used with the human Nav1.7 and Nav1.4.  Current evoked by 
the last pulse of the protocol was 84.6 ± 1.3% (n = 11) less than current evoked 
by the first pulse of the protocol for the wild-type rat Nav1.4 in the presence of 2 
μM TFP (Figure 10D).  All three mutant channels showed significantly attenuated 
use-dependent decreases in current produced by high frequency stimulation in 
the presence of 2 μM TFP compared to the wild-type rat Nav1.4 channel (Figure 
10D).  The decreases observed in the presence of 2 μM TFP were 44.1 ± 1.7% 
(n = 5), 23.3 ± 5.4% (n = 5), and 35.2 ± 5.0% (n = 6) for LA binding-site mutant 
channels N434K, L1280K, and F1579K, respectively (Figure 10D).  However, the 
attenuated use-dependent decrease observed for the L1280K channel might not 
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accurately reflect a decreased sensitivity of the channel to use-dependent 
inhibition brought on by TFP because 2 μM TFP decreased the steady-state 
L1280K current to the point at which additional use-dependent inhibition was 
difficult to determine.  Therefore we also examined current produced from the LA 
binding-site mutant channels and the wild-type channel after high frequency 
stimulation (5 Hz) in the presence of 500 nM TFP in an attempt to limit the initial 
effects on the L1280K channel.  Results show that 500 nM TFP produced a use-
dependent decrease of 72.1 ± 2.7% (n = 8) in current evoked by the last pulse of 
the protocol compared to current evoked by the first pulse of the protocol for the 
wild-type rat Nav1.4 channel.  The decreases observed for channels containing 
mutations N434K, L1280K, or F1579K in the LA binding site were 14.7 ± 2.2% (n 
= 6), 33.2 ± 3.8% (n = 6), and 15.1 ± 1.9% (n = 8), respectively.  All of these 
observed use-dependent decreases were significantly attenuated compared to 
the use-dependent decreases seen with the wild-type rat Nav1.4 channel. 
Interestingly, the steady-state inactivation curves for each of the local 
anesthetic binding site mutant channels, in the absence of TFP, show that the 
N434K and F1579K mutations shifted steady-state inactivation of the channel in 
the depolarizing direction while the L1280K mutation shifted it in the 
hyperpolarizing direction compared to the wild-type channel (Figure 11).  
Therefore with a holding potential of -100 mV, more of the L1280K channels are 
in the inactivated state than the N434K or F1579K channels and this raises the 
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Figure. 11.  Steady-state inactivation curves of rat wild-type channels (n = 
11) and rat channels having the mutations N434K (n = 10), L1280K (n = 9), 
or F1579K (n = 10) in the LA binding site.  
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possibility that the differential effect of TFP on the mutant channels could be 
influenced by the differential shifts in steady-state inactivation and may not reflect 
differences in state-dependent binding.  To address this, protocols designed to 
examine TFP interaction with either the inactivated or closed state of the 
channels were used.  To examine TFP binding to the inactivated state of the 
channels, cells were held at -120 mV and pre-pulsed to -60 mV (wild-type, 
L1280K and F1579K channels) or -40 mV (N434K channels) for 10 seconds, 
pulsed to -120 mV for 100 ms to allow for recovery from fast inactivation, and 
then pulsed to 0 mV to elicit current.  The steady-state inactivation curve for 
N434K and F1579K show a considerable amount of current available at -60 mV 
(~ 35—45%) compared to WT channels (Figure 11) and therefore to ensure that 
the mutant channels were inactivated to the same extent as WT channels, the 
cells expressing N434K and F1579K channels were pre-pulsed to -40 mV and -
50 mV, respectively, instead of -60 mV.  At -40 mV 96% of the N434K channels 
are inactivated, which is similar to the 97% of F1579K channels inactivated at -50 
mV and 95% of WT channels inactivated at -60 mV.  An initial current was 
measured in the absence of drug and a second current was measured in the 
presence of 500 nM TFP.  After application of 500 nM TFP, only 21.9 ± 5.1% (n = 
8) of the rat wild-type Nav1.4 current remained (Figure 12A).  The percentage of 
currents remaining for LA mutant channels N434K, L1280K, and F1579K after 
500 nM TFP application were 75.9 ± 6.6% (n = 6), 33.3 ± 3.2% (n = 6), and 71.3 
± 10.3% (n = 6), respectively (Figure 12A).  The percentage of remaining current 
was used to estimate the IC50 for TFP by using the equation: (% remaining 
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current)/((1-% remaining current) x [TFP]).  The estimated IC50 of TFP for the 
inactivated state of the rat wild-type Nav1.4 channel is approximately 140 nM.  
The estimated IC50’s for TFP on the inactivated state of the N434K, L1280K, and 
F1579K channels are approximately 1.6 μM, 250 nM, and 1.2 μM, respectively.  
Although all mutant channels had more peak current remaining compared to the 
peak current remaining in the wild-type rat Nav1.4, only the LA binding-site 
mutant channels N434K and F1579K showed a significance difference from the 
wild-type channel.   
To examine TFP binding to the closed state of the channels, cells were 
pulsed to -140 mV for 10 seconds before pulsing to 0 mV to elicit a current.  We 
were not able to see any significant changes in the percentage of remaining 
current from control conditions after application of 500 nM TFP.  Therefore, we 
increased the concentration of TFP to 2 μM to see if we could observe 
differences in inhibition of channels in the closed state.  After application of 2 μM 
TFP the wild-type rat Nav1.4 had 93.0 ± 4.5% (n = 8) channel current remaining 
(Figure 12B) and, based on this data, the estimated IC50 of TFP for the closed 
state of the rat wild-type Nav1.4 is approximately 27 μM.  LA mutant channels 
N434K and F1579K after 2 μM TFP application had 103.9 ± 2.5% (n = 6) and 
97.4 ± 3.8% (n = 8) of their current remaining, respectively, and these effects 
were not significantly different than those seen with the wild-type rat Nav1.4 
(Figure 12B).  The L1280K mutant channel, however, showed a significant 
decrease in percent of remaining current in the presence of 2 μM TFP, with only 
41.6 ± 3.3% (n = 5) remaining (Figure 12B).  The estimated IC50’s for TFP on the 
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Figure 12.  State-dependent inhibitory effects of 500 nM TFP on the rat 
Nav1.4 wild-type channel and rat channels having the mutations N434K, 
L1280K, or F1579K in the LA binding site.  A, percentage of control current 
remaining after application of 500 nM TFP to rat wild-type and LA mutant 
channels in their inactivated state.  For the N434K channel, the pre-pulse voltage 
was – 40 mV to ensure inactivation of the channels.  B, Percentage of control 
current remaining after application of 2 μM TFP to rat wild-type and LA mutant 
channels in their closed state.  Statistical significance was determined using one-
way ANOVA analysis followed with a Tukey’s comparison test (* = p < 0.05).  
Statistical comparisons were made against WT values. 
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closed state of L1280K and F1579K channels are approximately 1.0 μM and 75 
μM, respectively.  The IC50 for TFP on the closed state of the N434K mutant 
channel could not be estimated due to the amount of current remaining after TFP 
treatment being over 100%.  However, it is probable that the IC50 value is greater 
that 75 μM.  Thus while the N434K and F1579K mutations reduced the apparent 
affinity of inactivated Nav1.4 for TFP, the L1280K mutation increased the 
apparent affinity of Nav1.4 in the closed state for TFP.  To further investigate the 
possibility that these lysine substitutions directly affect TFP interaction rather 
than indirectly attenuating TFP inhibition by altering the inactivation of the 
untreated channel, the effects of TFP on the development of channel inhibition as 
well as on recovery from inhibition were examined.  Surprisingly, the N434K 
channels showed an enhanced (~ 2.5 x) development of inhibition by 2 µM TFP 
compared to WT channels while the F1579K channels showed a slower (~ 12 x) 
development of inhibition by 2 µM TFP (Table 1).  Based on the rates of channel 
inhibition by TFP observed for WT and N434K, channels, inactivating pre-pulses 
used for examining recovery from channel inhibition by TFP were set at 200 ms.  
However, based on the rate of channel inhibition, a 200 ms pre-pulse would not 
be long enough to allow for adequate drug-binding to F1579K channels, and 
therefore a 500 ms inactivating pre-pulse was used for examining recovery of 
F1579K from inhibition by TFP.  Table 1 shows the N434K and F1579K channels 
recover from 2 µM TFP inhibition approximately 4.5 and 3 times faster than do 
WT channels, respectively.  These results indicate while the N434K enhances 
the onset of TFP interaction with inactivated Nav1.4, the F1579K mutation 
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 Table 1.  Time constants for onset of TFP inhibition and recovery from 
TFP inhibition for WT, N434K, and F1579K channels. 
 
 2 µM TFP 
Channel Recovery tau (ms) Development tau (ms) 
WT 1530 ± 170 51 ± 5 
N434K 347 ± 12* 20 ± 2† 
F1579K 502 ± 13* 655 ± 53† 
 
Values are means ± S.E.M.  Data was examined using a one-way ANOVA.  * 
value is significantly (p < 0.05) different from WT recovery tau.  † Value is 
significantly (p < 0.05) different from WT development tau.   
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attenuates the onset of TFP interaction with the channel, and both mutations 
accelerate TFP unbinding from the inactivated Nav1.4.  These results strengthen 
the evidence that the differential effect of TFP on the mutant channels are due to 
differences in direct binding of the drug to the channel.  
B.  A channel mutation associated with primary hereditary erythromelalgia 
(N395K) alters electrophysiological properties of Nav1.7 in addition to decreasing 
channel sensitivity to the local anesthetic lidocaine 
1.  The N395K mutation alters electrophysiological properties of Nav1.7 
The above results show a lysine substitution at the N434 residue (N434K) 
in the rat Nav1.4 sodium channel reduces TFP inhibition of the channel.  This 
same mutation causes decreased local anesthetic block of Nav1.4 (Nau et al., 
1999).  One hereditary erythromelalgia mutation that has been associated with a 
severe phenotype is the N395K Nav1.7 mutation (Drenth et al., 2005), located in 
the S6 segment of domain I.  This residue corresponds to the N434 residue in rat 
and human Nav1.4 channels.  Therefore, it was predicted that the N395K 
mutation in Nav1.7 alters interaction of local anesthetics with the channel.  Wild-
type (WT) hNav1.7 or the mutant derivative channel N395K were transiently 
expressed with hβ-1 and hβ-2 subunits in HEK293 cells.  An initial comparison of 
current traces from both channels did not suggest any major differences in 
channel kinetics (Figure 13, A and B).  The voltage-dependence of activation was 
measured for each channel using a series of depolarizing test pulses from -100 
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Figure 13.  Comparison of the activation properties between the WT and 
N395K Nav1.7 channels.  A and B, representative current-voltage (IV) traces for 
HEK293 cells transfected with WT (A) or N395K (B) channels.  Both channels 
were coexpressed with the human β1 and β2 subunits.  C and D, the IV 
relationship (C) and steady-state conductance curve (D) for N395K was 
hyperpolarized compared to WT.  Conductance was calculated using the 
equation ( )NaEV
Ig −=  where g = conductance, I = measured current, V = 
command voltage, and ENa = estimated reversal potential for Na+ ions.   
 64
to +70 mV.  N395K channels exhibited a hyperpolarized current-voltage (IV) and 
conductance-voltage (GV) curve compared to wild-type channels (Figure 13, C 
and D).  The midpoint of activation (estimated using a Boltzmann function) was 
significantly (p < 0.05) more negative (-28.0 ± 1.1 mV; slope: 6.7 ± 0.1 mV-1; n = 
18) for N395K channels than for WT channels (-20.3 ± 0.8 mV; slope: 7.27 ± 0.1 
mV-1; n = 19; Student’s unpaired t-test).  The voltage-dependence of steady-state 
fast inactivation was also evaluated for each channel using the protocol shown in 
Figure 14A and, in contrast to activation, did not differ between the WT and 
mutant channels (Figure 14, B and C).  The midpoint of steady-state fast 
inactivation for the WT channels (-71.3 ± 0.8 mV; slope: 6.79 ± 0.2 mV-1; n = 19) 
was not significantly different (p = 0.76) from that of the N395K channels (-70.9 ± 
1.1 mV; slope: 6.14 ± 0.1 mV-1; n = 18; Student’s t-test).   
Next, effects of the N395K mutation in Nav1.7 on steady-state slow 
inactivation were examined.  Mutations impairing steady-state slow inactivation in 
voltage-gated sodium channels have been implicated in hyperkalemic periodic 
paralysis, hereditary erythromelalgia, and epilepsy (Cummins & Sigworth, 1996; 
Bendahhou et al., 1999; Bendahhou et al., 2002; Rhodes et al., 2005; Cummins 
et al., 2004).  It has further been shown that mutations in residues corresponding 
to N395 in the skeletal muscle Nav1.4 channel (N434) and the brain Nav1.2 
channel (N418) alter slow inactivation (Wang & Wang, 1997; Nau et al., 1999; 
Chen et al., 2006).  Figure 14D shows that steady-state slow inactivation was 
tested by holding the cells at -120 mV and stepping to an inactivating pre-pulse 
(ranging from -130 to 10 mV) for 30 s.  This was followed by a 100 ms pulse to 
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Figure 14.  Comparison of electrophysiological properties between the WT 
and N395K Nav1.7 channels.  A, Protocol used to examine steady-state fast 
inactivation.  B, Representative traces of WT and N395K currents produced after 
pulsing to the indicated voltage for 500 ms.  C, The steady-state fast inactivation 
curves for WT and N395K channels were not significantly different.  D, Protocol 
used to examine steady-state slow inactivation.  E, Representative traces of WT 
and N395K currents produced after pulsing to the indicated voltage for 30 s.  F, 
The N395K channel showed an impaired steady-state slow inactivation curve 
compared to WT.  G, Protocol used to examine deactivation.  H, Representative 
traces of WT and N395K currents produced during a 0.5 ms pulse to 0 mV 
followed by a 30 ms pulse to -45 mV.  Deactivation time constants were 
determined using a single exponential fit to the rate of current decay during the 
30 ms pulse to the indicated voltages.  I, N395K channels displayed a slightly 
slower onset of deactivation than that of WT.   
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-120 mV to allow recovery from fast inactivation and a test pulse to -10 mV for 25 
ms to assess the fraction of current remaining available for activation.  The 
change in channel availability measured with this protocol reflects the fraction of 
channels that undergo slow inactivation.  Figure 14E shows representative traces 
of WT and N395K current produced following a 30 s pulse to the indicated 
voltage.  N395K channels showed an impaired steady-state slow inactivation 
compared to WT channels (Figure 14F).  The midpoint of steady-state slow 
inactivation for N395K channels (-33.6 ± 2.6 mV; slope: 11.8 ± 0.2 mV-1; n = 6) 
was significantly (p < 0.05) depolarized compared to WT channels (-46.7 ± 1.7 
mV; slope: 16.1 ± 1.0 mV-1; n = 6; Student’s unpaired t-test).   
The kinetics of deactivation for WT and N395K channels was also 
examined (protocol shown in Figure 14G) by eliciting tail currents at a range of 
potentials after brief activation of the channels (0 mV for 0.5 ms).  Deactivation 
reflects the transition of the channel from the open to closed state, and defects in 
skeletal muscle sodium channel deactivation have been implicated in 
paramyotonia congenita (Featherstone et al., 1998).  Figure 14H shows an 
example of WT and N395K tail currents elicited by pulsing to -45 mV for 30 ms 
following a 0.5 ms pulse to 0 mV.  The traces demonstrate the N395K channels 
undergo deactivation slower than WT channels.  The time constant of 
deactivation (measured with single exponential fits) was slower for the N395K 
channel than that of the WT channel at potentials ranging from -100 mV to -40 
mV (Figure 14C).  The change in the kinetics of deactivation is consistent with 
the hyperpolarizing shift in the voltage-dependence of activation.   
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2. The N395K mutation decreases Nav1.7 sensitivity to lidocaine 
As mentioned earlier, lysine substitution at the residue corresponding to 
N395 in rat skeletal muscle Nav1.4 channel (N434) reduced the affinity for both 
amitriptyline and local anesthetics for inactivated channels (Nau et al., 1999; 
Wang et al., 2004; Nau & Wang, 2004).  Therefore, the impact of the N395K 
mutation on local anesthetic binding to Nav1.7 was tested.  Inhibition of channel 
current by a range of lidocaine concentrations (10 μM—10 mM) was examined 
for WT and N395K channels in the inactivated and resting state.  Lidocaine 
binding to the inactivated state of the channels was tested by holding the cells at 
-120 mV and stepping to an inactivating pre-pulse (-50 mV) for 10 s, which is 
sufficient to inactivate all of the channels.  This was followed by 100 ms pulses to 
-120 mV to allow recovery from fast inactivation, and the fraction of current 
remaining was measured in the absence and presence of lidocaine with a 20 ms 
test pulse to -10 mV.   
Potency, but not efficacy, of lidocaine inhibition of inactivated N395K 
channels was attenuated compared to WT (Figure 15A).  No data was obtained 
using lidocaine concentrations greater than 10 mM due to toxicity to the cells.  
Using a one-site binding fit, the IC50 of lidocaine for inactivated WT channels was 
estimated at 500 μM while the IC50 for inactivated N395K channels was 
estimated at 2.8 mM.  However, the one-site binding model did not produce a 
good fit for the dose-inhibition relationship of lidocaine and inactivated WT 
channels.  The data show that between 100 and 300 µM, lidocaine inhibition of 
WT inactivated channels reaches a plateau before increasing at doses of 1 mM 
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Figure 15.  Effects of lidocaine on inactivated and resting WT and N395K 
channels.  A, Dose-response of lidocaine inhibition was attenuated on 
inactivated N395K channels at all concentrations of lidocaine tested compared to 
inactivated WT.  Two-site binding fit was used for WT (R2 = 0.99) and a one-site 
binding fit was used for N395K (R2 = 0.98) B, Dose-response of lidocaine 
inhibition was attenuated on resting N395K channels for 3 and 10 mM lidocaine 
compared to resting WT.  A one-site binding fit was used for both WT (R2 = 0.91) 
and N395K (R2 = 0.92) channels.  Data are presented as mean % inhibition of 
peak current ± S.E.M. (* = p < 0.05).   
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and higher (Figure 15A).  It was hypothesized that this plateau in the relationship 
was due to more than one-site being available for lidocaine binding.  A two-site 
binding model gave a better fit to the WT data (R2 = 0.99) than did a one-site 
binding model (R2 = 0.68).  The two-site binding model fit indicated that there are 
possibly two states of the WT sodium channels at -50 mV, one state that exhibits 
high affinity lidocaine binding while the other exhibits low affinity binding.  Based 
on the two-site fit, the IC50 of lidocaine for the high affinity and low affinity binding 
to WT channels was 210 µM and 4.3 mM, respectively.  The high affinity and low 
affinity populations may represent channels in different inactivated conformations 
(see discussion). These data show that the N395K mutation significantly reduced 
lidocaine inhibition of Nav1.7 channels at -50 mV, especially the high affinity 
binding. 
Lidocaine binding to the resting state of the channels was tested by 
holding the cells at -120 mV and stepping to a pre-pulse of -140 mV for 10s.  The 
fraction of current remaining was assessed by a test pulse to -10 mV for 25 ms.  
Lidocaine had little or no effect on resting WT and N395K channels at low 
concentrations (10 μM—1 mM) while showing more inhibition at higher 
concentrations (3 mM, 10 mM) (Figure 15B).  Using a one-site binding fit, the IC50 
of lidocaine for resting WT channels was estimated at 4.3 mM while the IC50 for 
resting N395K channels was estimated at 7.9 mM.  In contrast to the inactivated 
channel data, a two-site binding model did not give a better fit to the WT resting 
channel data.  These data indicate the N395K mutation reduced the inhibition of 
resting channels by lidocaine, although to a lesser extent than that at -50 mV.   
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Figure. 16.  Use-dependent inhibition of WT and N395K current by 
lidocaine.  A, example of peak WT currents during high frequency stimulation 
under control conditions (left) and in the presence of 300 μM lidocaine (right).  B, 
example of peak N395K currents during high frequency stimulation under control 
conditions (left) and in the presence of 300 μM lidocaine (right).  C, Ratio of  peak 
WT and N395K currents from the first pulse to the last pulse of the high 
frequency stimulation protocol in the presence of different concentrations of 
lidocaine.  Data are presented as mean % decrease in current between the 1st 
and 20th pulse ± S.E.M. (* = p < 0.05).   
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As local anesthetics are known to exhibit use-dependent inhibition of 
sodium currents, it was important determine if the N395K channels showed less 
use-dependent inhibition by lidocaine when compared to WT channels.  Use-
dependent effects were studied by pulsing the transfected cells to -10 mV at a 
frequency of 5 Hz in the absence and presence of drug.  Figure 16 (A and B) 
displays examples of results under control conditions (left) and in the presence of 
300 μM lidocaine (right) for both the WT and N395K channels.  WT current 
amplitude decreased 10.4 ± 3.3 % (n = 6), 18.1.4 ± 3.2 % (n = 6), 27.8 ± 3.3 % (n 
= 11), and 42.7 ± 2.0 % (n = 7) from the first pulse to the last pulse of the 
protocol in the presence of 10, 30, 100, 300 μM lidocaine, respectively (Figure 
16C).  Decreases in N395K current amplitude were significantly (p < 0.05) 
smaller than decreases in WT current (one-way ANOVA followed by Tukey’s 
comparison test) at 30, 100, 300 μM lidocaine (Figure 16C).  Decreases 
observed for the N395K channel were 2.4 ± 0.6 % (n = 6), 1.7± 0.6 % (n = 5), 4.3 
± 0.6 %, (n = 6) and 11.0 ± 2.6 %, (n = 5) for 10, 30, 100, 300 μM lidocaine, 
respectively.  
3. An erythromelalgia mutation not found in the local anesthetic binding 
site (F216S) did not alter Nav1.7 sensitivity to lidocaine   
Although the N395K mutation in Nav1.7 showed resistance to inhibition by 
lidocaine, it is possible that other hereditary erythromelalgia mutations outside of 
the local anesthetic binding site might also alter lidocaine sensitivity.  We 
therefore investigated the effects of lidocaine on Nav1.7 containing another 
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mutation (F216S) that has been identified in erythromelalgia patients (Drenth et 
al., 2005).  A recent study shows that the F216S channel has a hyperpolarized 
voltage-dependence of activation similar to the N395K mutation, but an 
enhanced steady-state slow inactivation (Choi et al., 2006).  We examined the 
effects of 300 μM and 1 mM lidocaine on inactivated F216S channels.  These 
concentrations of lidocaine were chosen because both showed considerable 
inhibition of the WT channel in the inactivated (-50 mV pre-pulse) state.   Figure 
17A shows that the level of inhibition of inactivated F216S channels by 300 μM 
(38.4 ± 2.1 %, n = 6) and 1 mM (58.2 ± 2.5 %; n = 5) were not significantly 
different from that of inactivated WT channels (300 μM: 39.9 ± 7.3 %, n = 11; 1 
mM: 55.9 ± 4.9 %, n = 9; Student’s unpaired t-test).  However, inhibition of 
inactivated F216S channels by 300 μM and 1 mM lidocaine was significantly (p < 
0.05) higher than inhibition of N395K channels by 300 μM (12.4 ± 1.3 %, n = 6) 
and 1mM lidocaine (26.2 ± 4.2 %, n = 8; Student’s unpaired t-test; Figure 17A).  
We also investigated use-dependent inhibition of F216S currents by 300 μM by 
pulsing cells transfected with F216S to -10 mV at a frequency of 5 Hz in the 
presence of lidocaine.  Figure 17B shows that F216S current amplitude 
decreased 42.7 ± 2.5 % (n = 6) from the first pulse to the last pulse of the 
protocol in the presence of 300 μM lidocaine and was not significantly different 
from the decrease seen with WT channels (42.7 ± 2.0 %, n = 11; one-way 
ANOVA followed by a Tukey’s comparison test).  This decrease in F216S current 
amplitude was significantly (p < 0.05) higher than the decrease in N395K current 
amplitude (11.0 ± 2.6 %, n = 5; one-way ANOVA followed by a Tukey’s 
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Figure 17.  Inhibitory effects of lidocaine on the F216S channel compared 
to Nav1.7 WT and N395K.  A,  Lidocaine (300 µM and 1 mM) inhibition of 
inactivated F216S channels compared to inactivated WT channels and to 
inactivated N395K channels.  B,  Ratio of peak F216S currents from the first 
pulse to the last pulse of the high frequency stimulation protocol in the presence 
300 µM and 1 mM lidocaine compared to that of WT and N395K channels.  Data 
are presented as mean % inhibition of peak current ± S.E.M or mean % decrease 
in current between the 1st and 20th pulse ± S.E.M (* = p < 0.05). 
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comparison test) induced by 300 μM lidocaine (Figure 17B).  These data show 
that a hereditary erythromelalgia mutation outside of the Nav1.7 local anesthetic 
binding site does not affect lidocaine sensitivity of Nav1.7. 
C.  Lidocaine stabilizes Nav1.7 in a configuration that decreases transition to the 
slow-inactivated state of the channel 
1. Lidocaine alters the recovery of Nav1.7 channels from inactivation 
As shown earlier, a two-site binding model gave a much better fit to the 
dose-response curve for lidocaine inhibition of Nav1.7 channel current.  This fit 
indicated there are possibly two interaction sites of Nav1.7 at -50 mV, one that 
exhibits high affinity lidocaine binding while the other exhibits low affinity binding.  
The hypothesis was the high affinity and low affinity populations represent 
channels in different inactivated conformations.  One explanation for this is the 
long pre-pulse (10 s) to -50 mV to test lidocaine inhibition of Nav1.7 results in 
some channels entering into a fast-inactivated state and others entering into a 
slow-inactivated state.  Slow-inactivated channels create a problem because they 
required prolonged hyperpolarizing pulses to recover.  This long recovery pulse 
is likely to allow for unbinding of lidocaine thus its interaction with the slow-
inactivated state may be masked.  A second explanation for the two-site binding 
interaction of lidocaine with Nav1.7 is at -50 mV the channels are a mixture of 
closed-inactivated and open-inactivated channels.  In 1980 it was demonstrated 
sodium channels can inactivate without opening (Bean, 1981).  One recent study 
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using squid giant axons showed closed-state inactivation is more likely to occur 
at hyperpolarized membrane potentials and less likely to occur as potentials 
become more depolarized (Armstrong, 2006).  Therefore, to investigate the state 
dependence of lidocaine inhibition, the recovery profile for Nav1.7 channels after 
being pulsed to various potentials for 10s in the absence and presence of 1 mM 
lidocaine was tested.  This would establish a rate of recovery for fast and slow-
inactivated channels at different potentials.   
Figure 18A displays the protocol used to examine the recovery from fast 
and slow inactivation for Nav1.7 channel.  For these experiments cells containing 
Nav1.7 were held at one of six different potentials  (-100, -80, -60, -50, -40, or 0 
mV) for 10 seconds in the absence and presence of 1 mM lidocaine and were 
allowed to recover to -120 mV for various durations before testing remaining 
current with a 20 ms pulse to 0 mV.  The normalized amount of current was then 
plotted versus the duration of the recovery time in order to determine time 
constants for recovery from inactivation.  All recovery of Nav1.7 channels not 
treated with lidocaine showed a two or three-phase recovery profile (Figure 18, B 
thru G).  The time constant values estimated from a non-linear curve fit for these 
two phases of recovery are in a summarized in Table 2.  Due to the prolonged 
pre-pulse duration the two-phase recovery profile for control conditions likely 
represents a recovery from a fast and a slow-inactivated state with tau 1 
representing the time constant for recovery of Nav1.7 from fast inactivation and 
tau 2 representing the time constant for recovery of Nav1.7 from slow 
inactivation.  A third tau value (Figure 18, E thru G) likely represents recovery  
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Figure 18.  Recovery from prolonged inactivation and lidocaine inhibition 
for Nav1.7 channels.  A,  protocol used for examining recovery from prolonged 
inactivation and lidocaine inhibition for Nav1.7 channels.  B (left), recovery profile 
of Nav1.7 channels from a 10 s pulse to -100 mV in the absence and presence of 
1 mM lidocaine.  B (right), representative traces of recovery current at various 
durations of recovery after a 10 s pulse to -100 mV in the absence and presence 
of 1 mM lidocaine.  C—G, recovery profiles of Nav1.7 channels from different pre-
pulse potentials.  The pre-pulse value is given at the top of each graph.  G (left), 
recovery profile of Nav1.7 channels from a 10 s pulse to 0 mV in the absence and 
presence of 1 mM lidocaine.  G (right), representative traces of recovery current 
at various durations of recovery after a 10 s pulse to 0 mV in the absence and 
presence of 1 mM lidocaine.  Tau values are given for each trace.  In the case of 
control conditions, the recovery profile fit better to a second or third-order 
exponential growth equation.  All fits had R2 > 0.90.  As mentioned in the text, 
this likely represents recovery from 2 or 3 different forms of channel inactivation: 
fast and 2 types of slow.   
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Table 2.  Estimated time constants recovery from prolonged inactivation 
and lidocaine inhibition for Nav1.7 channels. 
 
No Lidocaine 1 mM lidocaine Pre-pulse 
voltage 
(mV) 
Tau 1 (ms) A1 Tau 2 (ms) A2 Tau 3 (s) A3 Tau (ms) 
-100 mV 4.63 +/- 1.6 0.14 1046 +/- 300 0.11 N/A N/A 220 +/- 16 
-80 mV 5.58 +/- 0.7 0.33 301 +/- 40 0.29 N/A N/A 137 +/- 7.2 
-60 mV 5.12 +/- 0.5 0.56 225 +/- 24 0.43 N/A N/A 112 +/- 5.3 
-50 mV 6.64 +/- 0.9 0.44 207 +/- 37 0.44 4.3 +/- 3.0 0.10 129 +/- 5.0 
-40 mV 6.55 +/- 0.8 0.36 200 +/- 27 0.49 2.8 +/- 1.1 0.14 147 +/- 5.0 
0 mV 6.22 +/- 4.3 0.21 245 +/- 26 0.61 4.9 +/- 1.4 0.18 189 +/- 12 
 
Values are means estimated from the best fit line produced from a second-order 
exponential growth function for the no lidocaine group and first-order exponential 
decay for the 1 mM lidocaine group.  The first-order exponential growth equation 
used is as follows: 11
tx
o eAyy += .  The second-order and third-order 
exponential growth equation used were as follows: 21 21
txtx
o eAeAyy ++=  and 
321
321
txtxtx
o eAeAeAyy +++=  where for both equations yo = the initial value at 
time 0, A1 = weight factor (of total recovered) for fraction recovered with time 
constant τ1, A2 = weight factor (of total recovered) for fraction recovered at τ2, A3 
= weight factor (of total recovered) for fraction recovered at τ3, x = the growth 
constant, and τ1 = time constant for recovery of fast-inactivated channels, τ2 and 
τ3 = time constants for the recovery of potentially two distinct slow-inactivated 
states of the channels.  N/A = not applicable.  The τ value for the lidocaine group 
represents the time constant for the recovery of channels from a drug bound 
state. 
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from a possible second slow-inactivated state produced from the 10 s pre-pulse.  
Recovery of Nav1.7 channels treated with 1 mM lidocaine displayed a one-phase 
profile and was fit using a first-order exponential growth equation for all pre-pulse 
voltages.  The time constant values estimated from a non-linear curve fit for 
mean values of recovery from lidocaine at each voltage can also be found in a 
summarized format in Table 2.  Figure 18, B and C, show that pulsing to -100 mV 
or -80 mV for 10 s does not completely inactivate Nav1.7 under control conditions 
but is sufficient to transition some of the channels into a state that recovers 
slowly.  Prolonged pulse durations (10 s) at -60, -50, -40 and 0 mV completely 
inactivate Nav1.7 and the fraction of channels exhibiting slow recovery increases 
with more depolarized conditioning pulses (Figure 18, D thru G).  When looking 
at the effects of 1 mM lidocaine, it is clear that recovery from inactivation is 
altered.  This indicates interaction of lidocaine with Nav1.7 induces a channel-
drug configuration that, at least initially, takes longer to recover than un-treated 
channels.  However, at more depolarized potentials (-50, -40, 0 mV) lidocaine 
paradoxically seemed to enhance the rate of recovery of Nav1.7 channels at 
prolonged durations compared to control (Figure 18, E thru G).  In addition, this 
enhancement of recovery rate by lidocaine corresponds to the durations at which 
the control channels were recovering from the slow-inactivated state.  Lidocaine 
enhances recovery from inactivation after recovery durations of approximately 
140 ms, 105 ms, and 75 ms for -50 mV, -40 mV, and 0 mV, respectively (Figure 
18, E thru G).  At shorter recovery durations at which control channels are 
recovering from a fast-inactivated state, 1 mM lidocaine still prolongs recovery.  
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These results indicate lidocaine reduces the transition of Nav1.7 channels to the 
state with slow recovery from inactivation while stabilizing a configuration that 
normally recovers quickly from inactivation.     
2. Lidocaine attenuates the ability of Nav1.7 channels to transition to a   
state that recovers slowly from inactivation 
Since lidocaine showed a difference in affecting the recovery of Nav1.7 
from a fast-inactivated state versus a slow-inactivated state, the next goal was to 
investigate the effects of lidocaine on the onset of slow inactivation in Nav1.7 
channels at the same membrane potentials used to examine recovery from 
inactivation.  To assure that relief from fast-inactivation was complete, the time 
constants for recovery (Table 2, tau 1) of Nav1.7 at -120 mV from fast inactivation 
at the different holding potentials used was multiplied by five and used as the 
recovery duration.  Therefore, when examining the onset of slow inactivation for 
holding potentials -100, -80, and -60 mV the recovery time was set at 30 ms 
while for holding potentials -50, -40, and 0 mV the recovery time was set at 40 
ms.  The protocol used to examine the onset of slow inactivation is shown in 
Figure 19A.  Pulsing to -100 mV did not induce any slow inactivation (Figure 
19B).  Pulsing to -80, -60, -50, -40, and 0 mV induced slow inactivation that 
developed with two distinct time courses in Nav1.7 (Figure 19, C thru F).  As the 
pulses became more depolarized the time constant for onset of the first slow-
inactivated state decreased indicating that stronger depolarizations are more 
effective at inducing slow-inactivation in Nav1.7.  As the pulses were prolonged, a  
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Figure 19.  Onset of slow inactivation and lidocaine inhibition for Nav1.7 
channels.  A, protocol used for examining onset of slow inactivation and 
lidocaine inhibition for Nav1.7 channels.  B (left), the onset of slow 
inactivation/lidocaine inhibition profile of Nav1.7 channels pulsed to -100 mV for 
increasing durations in the absence and presence of 1 mM lidocaine.  B (right), 
representative traces of current produced after various pulse durations to -100 
mV in the absence and presence of 1 mM lidocaine.  C—G, onset of slow 
inactivation/lidocaine inhibition profiles of Nav1.7 channels from different pulse 
potentials.  The pulse value is given at the top of each graph.  G (left), the onset 
of slow inactivation/lidocaine inhibition profile of Nav1.7 channels pulsed to 0 mV 
for increasing durations in the absence and presence of 1 mM lidocaine.  G 
(right), representative traces of current produced after various pulse durations to 
0 mV in the absence and presence of 1 mM lidocaine. Tau values are given for 
each trace.  In the case of control conditions, the onset profile fit better to a 
second-order exponential growth equation possibly due to the onset of 2 different 
forms of channel slow inactivation.  All fits had R2 values > 0.90. 
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Table 3.  Estimated time constants for onset of slow inactivation for Nav1.7 
channels. 
 
No Lidocaine Pre-pulse 
voltage 
(mV) 
Tau 1 (ms) A1 Tau 2 (ms) A2
-100 mV N/A N/A N/A N/A 
-80 mV 1300 +/- 120 0.24 12400 +/- 9100 0.05 
-60 mV 633 +/- 49 0.45 10400 +/- 3300 0.15 
-50 mV 540 +/- 50 0.45 11100 +/- 3100 0.21 
-40 mV 508 +/- 48 0.46 14200 +/- 3300 0.31 
0 mV 339 +/- 49 0.40 6510 +/- 785 0.52 
 
Values are means estimated from the best fit line produced from a first-order or a 
second-order exponential growth.  For -100 mV, no onset of slow inactivation 
was observed and therefore time constants could not be obtained.  The first-
order exponential growth equation used is as follows: 11
tx
o eAyy += The 
second-order exponential growth equation used is as 
follows: 21 21
txtx
o eAeAyy ++=  where for both equations yo = the initial value at 
time 0, A1 = weight factor (of total inactivated) for fraction inactivated with time 
constant τ1, A2 = weight factor (of total inactivated) for fraction inactivated at τ2,, x 
= the decay constant, and τ1 and τ2 = time constant for the onset of initial and 
prolonged slow inactivation in Nav1.7 channels, respectively.   
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Table 4.  Estimated time constants for onset of lidocaine inhibition of 
Nav1.7 channels. 
 
1 mM Lidocaine Pre-pulse 
voltage 
(mV) 
Tau 1 (ms) A1 Tau 2 (ms) A2
-100 mV 591.6 +/- 19.5 N/A N/A N/A 
-80 mV 238.5 +/- 6.7 N/A N/A N/A 
-60 mV 72.3 +/- 1.5 N/A N/A N/A 
-50 mV 33.4 +/- 1.1 N/A N/A N/A 
-40 mV 14.27 +/- 0.38 0.65 5094 +/- 1600 0.06 
0 mV 8.29 +/- 0.39 0.71 5967 +/- 760 0.21 
 
Values are means estimated from the best fit line produced from a first-order or a 
second-order exponential growth.  The first-order and second-order exponential 
growth equations used were the same as used in Tables 2 and 3.  Only at pulse 
voltages of -40 and 0 mV was the second-order exponential growth equation 
required.  Again, A1 = weight factor (of total inhibited) for fraction inhibited with 
time constant τ1, A2 = weight factor (of total slow-inactivated) for fraction of 
channels inactivated at τ2, x = the decay constant, and τ1 and τ2 = time constant 
for the onset of lidocaine inhibition and prolonged slow inactivation in the 
presence of lidocaine for Nav1.7 channels, respectively. 
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second slow-inactivation time course on the order of seconds could be observed 
at each potential (excluding -100 mV).  The estimated time constants for onset of 
slow inactivation in Nav1.7 channels are summarized in Table 3.  The application 
of 1 mM lidocaine enhanced the transition of the Nav1.7 channel to a non-
conducting state at all pre-pulse potentials (Figure 19, B thru F).  This non-
conducting state corresponds to a drug bound state of the channel.  The 
estimated time constants for the onset of lidocaine inhibition of Nav1.7 channels 
are summarized in Table 4.  Interestingly, after an initial fast decrease in current 
caused by lidocaine, inhibition levels off and very little additional drop in current is 
observed (Figure 19, B thru F).  This is seen at all pre-pulse potentials including -
100 mV.  With increasing durations of depolarization this leveling off of current 
inhibition by lidocaine takes place at approximately the same time as slow 
inactivation is starting to occur in control channels.  The dashed line in Figure 19 
(B thru F) represents the approximate time at which slow inactivation begins to 
occur in control channels.  As shown, the dashed line intersects with the time 
course of lidocaine inhibition on Nav1.7 channels approximately where no 
additional inhibition can be observed.  This raises the possibility that transition of 
Nav1.7 into a slow-inactivated state decreases or abolishes the ability of lidocaine 
to interact with the channel.  However, at pre-pulses of -40 or 0 mV, a second 
slow-inactivated state can be seen in lidocaine treated channels suggesting 
some slow inactivation may still take place in the presence of lidocaine given the 
depolarization is strong enough.  In addition, when pulsing to 0 mV for 
approximately 6s or longer, lidocaine attenuates the magnitude of current 
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decrease compared to the decrease observed in control channels.  This result is 
consistent with lidocaine interfering with the ability of Nav1.7 channels to 
transition to a state that recovers slowly from inactivation. 
3. Lidocaine exhibits different dose-response effects on Nav1.7 current 
which are dependent on voltage and pulse duration   
If the high affinity and low affinity populations represent channels in fast 
and slow-inactivated states, then lidocaine should display different concentration-
response effects on channels pulsed to various potentials for 200 ms versus 10 
s.  The reason for this is that a 200 ms pulse would produce minimal transition to 
slow-inactivation in Nav1.7 channels as opposed to a 10 s pulse which is efficient 
at inducing slow-inactivation.  Therefore, Nav1.7 channels were pulsed to the 
same potentials used previously for either 200 ms or 10 s protocols and shown in 
Figure 20A.  Protocols were run before and after the application of 1 mM 
lidocaine and were analyzed as paired experiments.  Dose-response effects of 
lidocaine on Nav1.7 channel current when pulsing for 200 ms are better fit with a 
one-site dose-response model for all pulse potentials (Figure 20B).  When 
pulsing Nav1.7 channels to the various potentials for 10 s, the dose-response 
effects of lidocaine on channel current fit better to a two-site binding model 
(Figure 20C).  This implies the extension of pulse duration transitions the Nav1.7 
channels into a mixture of high affinity and low affinity configurations that interact 
with lidocaine.  The IC50 values estimated for each voltage and duration are  
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Figure 20.  Dose-response curves of lidocaine inhibition of the Nav1.7 at 
various holding potentials.  A recovery pulse of 40 ms (for -100, -80, -60 mV 
pulses) and 30 ms (for -50, -40, 0 mV pulses) to -120 mV was given after each 
conditioning pulse.  A,  Dose-response curves of lidocaine inhibition of the Nav1.7 
when holding at the indicated potential for 200 ms.  Data were fit using a one-site 
binding equation.  B,  Dose-response curves of lidocaine inhibition of the Nav1.7 
when holding at the indicated potential for 10 s.  As seen previously in Figure 15, 
these data fit better using two-site binding equation.  The one-site and two-site 
binding equations are explained in Table 5.  All fits had R2 > 0.90. 
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Table 5.  Summary of IC50 values established for lidocaine inhibition of 
Nav1.7 current at different potentials and pulse durations.   
 
 Pulse Duration 
 200 ms  10 s 
Voltage (mV) IC50 (µM) IC50 1(µM) IC50 2 (mM) 
-100 mV 727 +/- 154 91.7 +/- 29.3 34.2 +/- 350 
-80 mV 234 +/- 44.0 15.1 +/- 3.4 2.26 +/- 2.6 
-60 mV 121 +/- 20.5 10.7 +/- 2.2 2.32 +/- 2.0 
-50 mV 110 +/- 19.7 7.92 +/- 2.2 2.12 +/- 1.7 
-40 mV 102 +/- 16.9 5.46 +/- 2.5 1.68 +/- 1.4 
0 mV 75.6 +/- 13.5 2.64 +/- 2.2 2.40 +/- 1.1 
 
Values are mean IC50 values ± S.E.M. estimated from the best fit line produced 
from a one-site or two-site binding equation.  The one-site binding equation was 
as follows:
xK
Bxy += .  The two-site binding equation was as follows: 
xK
xB
xK
xBy +++= 2
2
1
1 .  For these equations, y = percentage lidocaine inhibition, x = 
lidocaine concentration, B = maximum amount of inhibition (thus B1 and B2 
represent max inhibition for the high and low affinity configuration of Nav1.7 for 
lidocaine, respectively), K = concentration at which 50% of Nav1.7 channels are 
inhibited (i.e. IC50 values, thus K1 and K2  represent IC50 values for the high and 
low affinity configuration of Nav1.7 for lidocaine, respectively).  The average n 
value for all concentrations of lidocaine was 6 with no single concentration having 
an n < 4.   
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summarized in Table 5.  When pulsing for 200 ms, the IC50 values get 
progressively smaller in response to depolarizing the pulse potential.  The first 
IC50 values established from pulsing Nav1.7 for 10 s also get progressively 
smaller in response to more depolarizing pulse potentials and are less than the 
IC50 values observed when pulsing the channel for 200 ms.  The second IC50 
values established for the 10 s pulse did not dramatically change with pulse 
potential.  The -100 mV pulse is the exception with an IC50 value of 34.2 ± 350 
mM.  The variability in this IC50 value reflects the possibility that the low affinity 
configuration (IC50 ~ 2 mM) is not established at a prolonged pulse to -100 mV.  
In addition, the onset of inactivation data shows Nav1.7 does not transition to a 
slow-inactivated state during prolonged pulses to -100 mV (Figure 19B).   
 To further examine the effects of pulse duration on lidocaine inhibition of 
Nav1.7 channels dose-response curves comparing the effects of  200 ms or 10 s 
pulses were plotted for each potential (Figure 21).  When pulsing to -100 or -80 
mV, it is clear that the 10 s pulse enhances lidocaine inhibition of Nav1.7 
compared to the 200 ms pulse (Figure 21, A and B).  As the pulse potentials 
become more depolarized the dose-response curves for the 10 s pulse and the 
200 ms pulse intersect with higher lidocaine concentrations showing more 
inhibition on Nav1.7 channels pulsed for 200 ms than ones pulsed for 10 s 
(Figure 21, C thru F).  The point of intersection for the separate dose-response 
curves was dependent on pulse potential.  For example, the point at which the 
200 ms pulse to -50 mV begins producing more lidocaine inhibition than the 10 s 
pulse to -50 mV was approximately at 260 µM (Figure 21D).  If the pulse is 
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Figure 21.  Dose-response curves of lidocaine inhibition on Nav1.7 
comparing the effects of pulse duration at various holding potentials on 
inhibition of channel current.  The potential at which the channel was pulsed is 
indicated at the top of each set of dose-response curves.  As mentioned 
previously dose-response data resulting from pulsing channels for 200 ms were 
fit using a one-site binding equation.  Dose-response data resulting from pulsing 
channels for 10 s were fit using a two-site binding equation. 
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changed to 0 mV, this point of intersection shifts to approximately 25 µM (Figure 
21F).  Interestingly, the point of intersection appears to happen during the 
plateau phase of the 10 s pulse dose-response curve for each potential.  Again, 
this is consistent with the Nav1.7 channel more effectively transitioning to the 
slow-inactivated state at depolarized potentials thus decreasing interaction of 
lidocaine with the channel.   
4. PEPD mutations I1461T and T1464I do not alter lidocaine effects on 
the activation of the Nav1.7 channel   
A recent study has shown that families affected by paroxysmal extreme 
pain disorder (PEPD), characterized by rectal, ocular, and submandibular pain, 
have missense mutations in the SCN9A gene encoding for Nav1.7 (Fertleman et 
al., 2006).  PEPD mutations reportedly attenuate the voltage-dependence of fast 
inactivation as well as decrease the overall magnitude of fast inactivation for 
Nav1.7 channels (Fertleman et al., 2006).  These characteristics were used to 
evaluate how altering fast inactivation of Nav1.7 may affect the lidocaine 
sensitivity of the channel.  The hypothesis would be that attenuating the transition 
of Nav1.7 to a fast-inactivated state will decrease the lidocaine sensitivity of the 
channel.  To test this, two mutations implicated in PEPD, I1461T and T1464I, 
were inserted separately in the Nav1.7 channel, and the effects of these 
mutations on channel function and lidocaine interaction were investigated.  
Figure 22 (B thru D) shows the current-voltage traces for WT, I1461T, and 
T1464I channels transiently transfected in HEK293 cells along with human β1 
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Figure 22.  Effects of 1 mM lidocaine on the voltage-dependence of 
activation and peak current for Nav1.7, I1461T, and T1464I channels.  A, 
electrophysiological protocol used to obtain the current-voltage (IV) relationship 
for Nav1.7, I1461T, and T1464I channels.  B-D, representative IV traces for 
Nav1.7 (B), I1461T (C), and T1464I channels (D).  E-G, summarized IV curves of 
control conditions, time-dependent controls, and 1 mM lidocaine for Nav1.7 (E), 
I1461T (F), and T1464I channels (G).  H, effects of lidocaine on peak current for 
Nav1.7, I1461T, and T1464I channels.  Data are represented as normalized 
current ± S.E.M.  The 1 mM lidocaine (adjusted = normalized to peak control) 
group reflects the IV curve produced from normalizing the data to the peak 
current produced from control conditions.  Statistical significance was determined 
using a one-way ANOVA analysis followed with a Tukey’s comparison test (*= p 
< 0.05).   
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and β2 subunits.  The protocol used to obtain current-voltage relationships is 
shown in Figure 22A.  Previous investigation showed the I1461T and T1464I 
mutations caused alterations in channel inactivation including a noticeable 
persistent current lasting several hundred milliseconds (Fertleman et al., 2006).  
In this study, the persistent currents were not as large (~ 4% of peak current) as 
shown previously (> 40 % of peak current) but were still present (Figure 22, B 
thru D).  The effects of 1 mM lidocaine on the voltage-dependence of activation 
and peak current for Nav1.7, I1461T, and T1464I channels were evaluated using 
paired experiments.  Control values for V1/2 of activation and peak current were 
measured and subsequently re-measured after application of 1 mM lidocaine.  
Controls were performed to measure any time-dependent changes that occurred 
in V1/2 of activation and peak current.  The values for V1/2 of activation for WT, 
I146T, and T1464I were -26.3 ± 1.5 (n = 11), -27.2 ± 0.7 (n = 14), and -27.6 ± 1.5 
mV (n = 11), respectively.  These values were not significantly different from one 
another (p > 0.05, One-way ANOVA analysis) indicating the I1461T and T1464I 
mutations do not affect the voltage-dependence of activation for Nav1.7 
channels.  After application of 1 mM lidocaine, the V1/2 of activation for WT 
(Figure 22E), I1461T (Figure 22F), and T1464I (Figure 22G) was hyperpolarized 
by -8.9 ± 0.3 (n = 6), -10.8 ± 0.7 (n = 7), and -8.4 ± 0.8 (n = 6).  However, for WT 
channels the time-dependent (~ 9 min.) shift in the V1/2 of activation (-11.5 ± 1.0 
mV; n = 5) was significantly larger (p = 0.03) than the shift caused by lidocaine.  
Yet the time dependent shifts in the V1/2 of activation for I1461T (-11.2 ± 1.3 mV; 
n = 7) and T1464I (-10.1 ± 1.3 mV; n = 5) were not significantly different (p > 
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0.05) from the shifts caused by lidocaine (Figure 22, F and G).  This indicates 
lidocaine has minimal effect the voltage-dependence of activation for Nav1.7 and 
the I1461T and T1464I mutations do not alter this effect.   
The I1461T and T1464I mutations did however have an effect on the 
decrease in peak current caused by the interaction of lidocaine with Nav1.7.  WT 
channels showed a 49.7 ± 3.0 % (n = 6) decrease in peak current after 
application of 1 mM lidocaine (Figure 22E).  This value reflects the percent 
decrease in current adjusted for a time-dependent increase in current that 
occurred in Nav1.7 channels.  I1461T and T1464I channels showed a 39.9 ± 1.3 
% (n = 7; Figure 22F) and a 37.9 ± 1.1 % (n = 6; Figure 22G) decrease in current 
after application of 1 mM lidocaine.  Both of these decreases in current were 
significantly smaller (p < 0.05) than the decrease in current observed in WT 
Nav1.7 channels caused by 1 mM lidocaine (Figure 22H).  These values were 
also adjusted for a time-dependent increase in current.  Taken together, these 
data indicate while the I1461T and T1464I mutations do not affect the V1/2 of 
activation for Nav1.7 channels, they do decrease the ability of lidocaine to inhibit 
peak current produced by Nav1.7.  In addition, this attenuation of lidocaine effect 
does not involve changes in Nav1.7 voltage-dependence of activation. 
5. PEPD mutations I1461T and T1464I alter inactivation of the Nav1.7 
channel  
 Since PEPD mutations I1461T and T1464I effectively decrease the 
lidocaine inhibition of Nav1.7 peak current without showing effects on the voltage 
 93
dependence of activation for the channel, it was possible this decrease in 
lidocaine inhibition of the channel was due to a decreased interaction with the 
inactivated state of the channel.  To examine this, the effects of the I1461T and 
T1464I mutations on the inactivation properties of the Nav1.7 channel were 
tested.  The voltage-dependence of steady-state fast-inactivation was examined 
for all the channels using the protocol shown in Figure 23A.  The I1461T and 
T1464I mutations both caused depolarizing shifts of the voltage-dependence of 
fast-inactivation of Nav1.7 channels (Figure 23C).  The V1/2 of fast activation for 
WT (-77.5 ± 1.4 mV; n = 11), was statistically different (p < 0.05) from those of 
I1461T (-60.8 ± 0.6 mV; n = 14) and T1464I (-63.7 ± 1.6 mV; n = 11).  The V1/2 of 
fast inactivation values for the I1461T and T1464I mutant channels were not 
statistically different.  In addition, the slope for the fast inactivation curve for WT 
(7.09 ± 0.1 mV-1; n = 11), was statistically different from the slopes of the I1461T 
(5.68 ± 0.1 mV-1; n = 14) and T1464I (5.53 ± 0.2 mV-1; n = 11) fast inactivation 
curves (p < 0.05 one-way ANOVA followed by a Tukey’s comparison test).  The 
slopes of the I1461T and T1464I steady-state inactivation curves did not 
significantly differ.  
 The protocol shown in Figure 23B was used to test the effects of I1461T 
and T1464I mutations on the slow inactivation properties of the Nav1.7 channel.  
The Nav1.7 channel produced a slow inactivation profile containing two distinct 
components that were fit with a double Boltzmann function instead of a single 
(Figure 23D).  The first component of Nav1.7 slow inactivation had a V1/2 value of  
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Figure 23.  Effects of the I1461T and T1464I mutations on the inactivation  
properties of the Nav1.7 channel.  A, Protocol used to examine the voltage-
dependence of fast inactivation for the Nav1.7 channel.  B, Protocol used to 
examine the voltage-dependence of slow inactivation for the Nav1.7 channel.  C, 
Voltage dependence of fast inactivation for the Nav1.7 WT, I1461T, and T1464I 
channels.  D, Voltage dependence of slow inactivation for the Nav1.7 WT, 
I1461T, and T1464I channels.  Slope factors of conductance-voltage and steady-
state inactivation curves were calculated using the general single Boltzmann 
function: ( ) ⎟⎠
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-83.1 ± 1.6 mV (n = 11) and the second component had a V1/2 value of -33.9 ± 
1.5 mV (n = 11).  The I1461T and T1464I mutations produced a profile that fits 
better with a single Boltzmann function giving V1/2 values of -56.6 ± 0.7 mV (n = 
14) and -53.5 ± 1.8 mV (n = 11), respectively (Figure 23D).  The first and second 
V1/2 values for the WT voltage-dependence of slow inactivation were statistically 
different (p < 0.05) from V1/2 values for both the I1461T and T1464I channels.  
The V1/2 values of slow activation for the I1461T and T1464I mutant channels 
were not statistically different.  The slopes for the first (6.08 ± 0.2 mV-1; n = 11) 
and second (13.4 ± 0.4 mV-1; n = 11) components of slow inactivation curve for 
WT were statistically different (p < 0.05) from each other.  The slopes of both the 
first and second component of slow inactivation for WT were statistically different 
(p < 0.05) from the slope of the I1461T (10.1 ± 0.4 mV-1; n = 14) slow inactivation 
curve.  However, only the slope of the first component for WT slow inactivation 
was statistically different (p < 0.05) from the slope the T1464I (13.0 ± 0.6 mV-1; n 
= 11) slow inactivation curve.  The slope of the second component for WT slow 
inactivation was not different from the slope the T1464I slow inactivation curve.  
These results demonstrate the voltage-sensitivity of slow inactivation for Nav1.7 
channels decreases as pulse voltages become more depolarized.  With more 
depolarized voltages increasing the probability of channel opening, it is possible 
the voltage-dependence of slow inactivation for Nav1.7 channels may differ 
between channels that have opened before inactivation and those that have not.  
The I1461T and T1464I mutations seem to eliminate this difference.    
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6. PEPD mutations I1461T and T1464I alter the effects of lidocaine on 
slow inactivation of the Nav1.7 channel but not fast inactivation  
The same protocols shown in Figure 23A and 23B were used to 
investigate the effects of 1 mM lidocaine on fast and slow inactivation properties 
of the Nav1.7 WT, I1461T, and T1464I channels.  The V1/2 values were 
determined before and after application of lidocaine, and a control experiment 
was also performed to determine any time-dependent shifts in V1/2 values.  The 
average time-dependent effects are represented by the dotted lines in Figure 24, 
A thru F.  All shifts in V1/2 values caused by lidocaine were determined after 
accounting for the time-dependent shift observed in non-treated channels.  
Application of 1 mM lidocaine to WT channels caused hyperpolarizing shifts of     
-15.2 ± 1.9 mV (n = 5) in the V1/2 of fast inactivation (Figure 24A).  The slope 
factor of the fast inactivation curve for Nav1.7 in the presence of lidocaine was 
12.6 ± 0.6 mV-1 (n = 5).  Application of the same concentrations of lidocaine to 
I1461T and T1464I channels caused hyperpolarizing shifts in the V1/2 of fast 
inactivation of -12.3 ± 0.5 mV (n = 7) and -13.2 ± 0.6 mV (n = 6), respectively 
(Figure 24, B and C).  The shifts in the V1/2 of fast inactivation caused by 1 mM 
lidocaine for the I1461T and T1464I channels were not statistically different (p > 
0.05) from the shift observed in the WT channel.  Following application of 1 mM 
lidocaine, the slope factors for of the fast inactivation curve for the I1461T and 
T1464I channels were 8.8 ± 0.2 mV-1 and 7.6 ± 0.2 mV-1, respectively.  Both of 
these slope factors were significantly different (p < 0.05) from that observed in 
WT channels after application of 1 mM lidocaine.  This indicates the I1461T and 
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T1464I mutations enhance the ability of lidocaine to increase the voltage 
sensitivity of Nav1.7 inactivation gating while not affecting the overall shift in the 
voltage-dependence of fast-inactivation by lidocaine.   
The effects of lidocaine on Nav1.7 WT, I1461T, and T1464I channels were 
different using a slow inactivation protocol than those when using a fast 
inactivation protocol.  As shown previously, WT channels display two 
components of slow inactivation (Figure 23D).  The addition of 1 mM lidocaine 
hyperpolarized the V1/2 value of the first component by -21.1 ± 0.6 mV to -108 ± 
2.4 mV (Figure 24D).  Lidocaine did not have a significant effect (p > 0.05; 
Student’s unpaired t test) on the slope factor of the first component (6.6 ± 0.2 
mV-1; n = 6) compared to the slope factor of the first component in time-
dependent control channels (6.08 ± 0.2 mV-1; n = 11).  The second component 
was nearly eliminated in the presence of lidocaine, comprising less than 7% of 
total normalized current (Figure 24D).  When treating the I1461T and T1464I 
channels with 1 mM lidocaine, the slow inactivation profiles for the channels 
appear to change from having one component to two components (Figure 24, E 
and F).  The first of the two components for I1461T and T1464I displayed V1/2 
values of -90.0 ± 1.1 mV (n = 7) and -93.7 ± 2.5 mV (n = 6), respectively (Figure 
24, E and F).  These values were significantly hyperpolarized compared to time-
dependent control values of non-treated I1461T and T1464I channels (p < 0.05; 
Student’s t test).  The first of the two slow inactivation components for lidocaine 
treated I1461T and T1464I channels displayed hyperpolarizing shifts in V1/2 
values of -26.7 ± 1.3 mV (n = 7) and -33.0 ± 2.3 mV (n = 6), respectively  
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Figure 24.  Effects of lidocaine on the fast and slow inactivation properties 
of the Nav1.7 WT, I1461T, and T1464I channels.  A thru C, effects of 1 mM 
lidocaine on the voltage-dependent properties of fast inactivation for Nav1.7 WT 
(A), I1461T (B), and T1464I (C) channels.  D thru F, effects of 1 mM lidocaine on 
the voltage-dependent properties of slow inactivation for Nav1.7 WT (D), I1461T 
(E), and T1464I (F) channels.  Traces represent inactivation profiles before and 
after lidocaine application.  Time-dependent control values for each channel are 
represented by the dotted lines in each figure.  Time-dependent recordings were 
obtained at the same time at which lidocaine would have been added to the bath 
solution.  
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(Figure 24, E and F).  Both of these observed shifts were significantly larger than 
those observed in lidocaine treated WT channels (p < 0.05 for I1461T; p < 0.05 
for T1464I; one-way ANOVA followed by a Tukey’s comparison test).  However, 
these shifts are difficult to interpret due to the I1461T and T1464I channels 
displaying only one slow inactivation component under control conditions.   
The second of the two slow inactivation components for lidocaine treated 
I1461T and T1464I channels displayed lower voltage sensitivity to slow 
inactivation at depolarized potentials than non-treated channels (Figure 24, E 
and F).  The second of the two components for I1461T and T1464I displayed V1/2 
values of -32.8 ± 1.2 mV (n = 7) and -30.1 ± 1.7 mV (n = 5), respectively (Figure 
24, E and F).  Since lidocaine eliminated the second component in the voltage-
dependence of slow inactivation for WT channels, these V1/2 values could not be 
compared to WT channels.  However, these V1/2 values were not significantly 
different from the V1/2 value of the second component for non-treated WT 
channels.  In addition these V1/2 values were significantly depolarized compared 
to time-dependent control values of non-treated I1461T and T1464I channels (p 
< 0.05; Student’s unpaired t test).  The slope factors for the second of the two 
slow inactivation components for lidocaine treated I1461T (11.4 ± 0.5 mV-1; n = 
7) and T1464I channels (13.2 ± 1.0 mV-1; n = 5) were not significantly different (p 
> 0.05; Student’s unpaired t test) than the time-dependent slope factor values of 
non-treated I1461T (12.5 ± 0.5 mV-1; n = 7) and T1464I channels (11.3 ± 1.0  
mV-1; n = 5) as well as the second component of non-treated WT channels (13.4 
± 0.4 mV-1; n = 11).  These findings suggest the presence of lidocaine produces 
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a voltage-dependence profile for I1461T and T1464I channels that is similar to 
non-treated WT channels.   
7. PEPD mutations I1461T and T1464I decrease use-dependent 
inhibition of the Nav1.7 channel by lidocaine 
Since lidocaine is known to exhibit use-dependent inhibition of sodium 
currents, the use-dependent effects of lidocaine on the Nav1.7 WT, I1461T, and 
T1464I channels were investigated by pulsing the transfected cells to -10 mV at a 
frequency of 5 Hz in the absence and presence of drug.  Figure 25, A thru C 
displays representative traces of the effects of 1 mM lidocaine on the current 
amplitude when the channel is stimulated at high frequency.  In the absence of 
lidocaine, Nav1.7 WT, I1461T, and T1464I channels had decreases in current 
amplitudes evoked by the first pulse to the current amplitudes evoked by the last 
pulse of 20.5 ± 2.5% (n = 5), 22.3 ± 2.0% (n = 7), and 13.5 ± 3.6% (n = 5) 
respectively (Figure 25D).  In the presence of 1 mM lidocaine decreases of 52.2 
± 4.1 % (n = 6), 30.9 ± 1.2 % (n = 7), and 31.6 ± 1.5 % (n = 6) were observed for 
WT, I1461T, and T14641, respectively (Figure 25D).  All of these decreases in 
peak current amplitudes were significant compared to decreases observed in the 
time-dependent controls (p < 0.05; Student’s t test).  However, use-dependent 
decreases in current amplitude by lidocaine in I1461T and T1464I channels were 
significantly smaller than the decrease observed in the WT channel (p < 0.05; 
one-way ANOVA followed by a Tukey’s comparison test). 
 101
  
Figure 25.  Use-dependent inhibition of Nav1.7 WT, I1461T, and T1464I 
current by lidocaine.  A thru C, representative traces of peak WT (A), I1461T 
(B), and T1464I (C) currents during high frequency stimulation in the presence of 
1 mM lidocaine.  D, ratio of peak WT, I1461T, and T1464I currents from the first 
pulse to the last pulse of the high frequency stimulation protocol for time-
dependent controls and in the presence of 1 mM lidocaine.  * represents a 
statistically significance difference from time-dependent controls.  # represents a 
statistically significance difference WT lidocaine treated.  Data are presented as 
mean % decrease in current between the 1st and 20th pulse ± S.E.M (*/# = p < 
0.05).   
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8. The I1461T and T1464I mutations alter the recovery of Nav1.7 
channels from inactivation 
Since lidocaine decreased the transition of I1461T and T1464I to a slow-
inactivated state at depolarized potentials, it was possible lidocaine enhances the 
ability of the I1461T and T1464I channel to recover after prolonged inactivation.  
Before this was determined, the recovery profile for I1461T and T1464I channels 
after being pulsed to -100 mV, -50 mV, or 0 mV for 10 s was established and 
compared to the recovery profile of WT channels.  The protocol used for 
determining recovery profiles of I1461T and T1464I channels is shown in Figure 
26A.  Figure 26 (B thru D) shows the comparison of the recovery profile for 
I1461T and T1464I channels compared to wild-type channels.  When pulsing 
I1461T (n = 4) and T1464I (n = 3) channels to -100 mV for 10 s, recovery from 
inactivation was similar to WT channels (Figure 26B).  Table 6 displays tau 
values for recovery from fast inactivation for I1461T and T1464I channels 
compared to WT channels.  These data indicate recovery from fast inactivation 
induced by -50 and 0 mV is faster for I1461T (n = 4) and T1464I (n = 3) channels 
than for WT channels.  However, when pulsing at these voltages the effects of 
the I1461T and T1464I mutations on recovery from fast inactivation differ (Figure 
26, C and D).  For the T1464I channels, initial recovery from the -50 mV 
conditioning pulse is greater than observed in WT and I1461T channels while 
initial recovery from the 0 mV conditioning pulse was similar to that of WT, but 
still greater than that of I1461T channels (Figure 26, C and D). 
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Figure 26.  The effects of the 
I1461T and T1464I mutation on 
recovery from prolonged 
inactivation for Nav1.7 channels.  
A, voltage protocol used to produce 
recovery from prolonged inactivation 
profiles for I1461T and T1464I 
Nav1.7 channels.  B—D, recovery 
profiles of Nav1.7 WT, I1461T, and 
T1464I channels from different pre-
pulse potentials.  The pre-pulse 
value is given at the top of each 
graph.  For these experiments, the 
channels were held at the indicated 
potential for 10 seconds before 
recovery pulses to -120 mV at 
various durations were elicited.  This 
was followed by a 20 ms test pulse 
to 0 mV to test for available current.  
All profiles were fit with either a 
second or third-order exponential 
growth equation.  All fits had R2 > 
0.90. 
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Table 6.  Estimated time constants of recovery from fast inactivation for 
Nav1.7 WT, I1461T, and T1464I channels. 
 
WT I1461T T1464I Pre-pulse 
voltage 
(mV) 
Tau  (ms) A Tau  (ms) A Tau (ms) A 
-100 mV 4.6 +/- 1.6 0.14 4.3 +/- 1.7 0.11 3.6 +/- 1.6 0.09
-50 mV 7.3 +/- 1.2 0.45 3.3 +/- 0.7 0.19 1.5+/- 0.3 0.40
0 mV 6.2 +/- 4.3 0.16 N/A N/A N/A N/A 
 
Values are means (± S.E.M.) estimated from the best fit line produced from the 
first component of a second or third-order exponential growth function.  When 
pulsing to 0 mV, recovery for a fast-inactivated state was not observed for I1461T 
and T1464I channels.  A = weight factor (of total recovered) for fraction 
recovered with time constant tau.  Tau = time constant for the fast recovery of 
Nav1.7 channels from inactivation. 
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For the I1461T channels pre-pulsed to -50 mV or 0 mV recovery from 
prolonged inactivation is slower than recovery observed in WT channels (Figure 
26, C and D).  This suggests the I1461T and T1464I mutations are altering the 
dynamics of fast inactivation by different means.  One possibility is the I1461T 
mutation enhances the transition of Nav1.7 to a slow-inactivated state in addition 
to the role it plays in impairing fast inactivation.  The T1464 residue may only 
play a role in fast inactivation and does not affect the recovery of Nav1.7 
channels from the slow-inactivated state.  
Table 7 displays tau values for recovery from the first slow inactivation 
component for I1461T and T1464I channels compared to WT channels.  At -100 
mV, there is some disparity in the estimated time constants of recovery for all 
three channels.  However, Figure 26 shows there is very little transition to an 
inactivated state for I1461T and T1464I channels at -100 mV.  This makes the 
comparison of tau values for all three channels at -100 mV difficult to interpret.  A  
Interestingly, the recovery from the first slow inactivation component at potentials 
of -50 mV and 0 mV for I1461T was considerably delayed compared to WT 
channels (Figure 26, C and D).  In contrast, recovery of T1464I channels from 
the first slow inactivation component at the same potentials was similar to WT 
(Figure 26, C and D).  These data suggest the I1461T and T1464I mutations may 
affect the recovery of the Nav1.7 channel from a closed slow-inactivated state in 
a similar manner while affecting the recovery from an open slow-inactivated state 
differently.
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 Table 7.  Estimated time constants of recovery from the first slow 
inactivation component for Nav1.7 WT, I1461T, and T1464I channels. 
 
WT I1461T T1464I Pre-pulse 
voltage 
(mV) 
Tau  (ms) A Tau  (ms) A Tau (ms) A 
-100 mV 1046 +/- 300 0.11 1400 +/- 400 0.08 1200 +/- 470 0.09
-50 mV 301 +/- 43 0.49 243 +/- 20 0.57 185 +/- 15 0.58
0 mV 245 +/- 26 0.74 334 +/- 24 0.60 213 +/- 21 0.78
 
Values are means (± S.E.M.) estimated from the best fit line produced from the 
first component of a second or third-order exponential growth function.  A = 
weight factor (of total recovered) for fraction recovered with time constant tau.  
Tau = time constant for the slow recovery of Nav1.7 channels from inactivation. 
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9. Lidocaine alters the recovery of I1461T and T1464I channels from 
inactivation differently than WT channels   
The effects of lidocaine on the recovery of I1461T and T1464I channels 
from inactivation were tested using the protocol shown in Figure 26A to 
determine if the I1461T and T1464I mutations alter the ability of Nav1.7 to 
recovery from lidocaine inhibition.  After pulsing to -100 mV, lidocaine delayed 
recovery from inactivation for both I1461T (n = 3) and T1464I (n = 3) channels 
(Figure 27, A and D).  After pulsing to -50 mV, lidocaine attenuated the fast 
recovery of T1464I (n = 3) channels but did not affect slow recovery compared to 
control conditions.  However, after pulsing T1464I (n = 3) channels to 0 mV, 
recovery from slow inactivation becomes faster while recovery from fast 
inactivation is similar to control conditions (Figure 27, E and F).  In contrast, 
lidocaine has little effect on the recovery of I1461T (n = 3) channels from fast 
inactivation after pulsing to -50 mV, but after pulsing to 0 mV, lidocaine enhances 
the recovery of I1461T (n = 3) channels from fast and slow inactivation (Figure 
27, B and C).   
To better understand how lidocaine may be interacting with WT channels, 
the information gathered on the effects of lidocaine on the recovery of I1461T 
and T1464I channels from inactivation was compared to the effects of lidocaine 
on the recovery of WT channels from inactivation.  Lidocaine suppressed 
recovery from fast inactivation in WT channels to a greater extent than it did for 
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Figure 27.  Lidocaine effects on recovery from prolonged inactivation at 
various potentials for Nav1.7 channels having the I1461T or T1464I 
mutation.  The protocol used for examining recovery from prolonged inactivation 
and lidocaine inhibition for I1461T and T1464I channels was the same as the one 
used in Figure 26A.  The pre-pulse value (duration = 10 s) is given at the top of 
each graph.  Under all conditions, the recovery profile was fit with a second-order 
exponential growth equation.  All fits had R2 > 0.90. 
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the I1461T and T1464I channels at -100 mV and -50 mV (Figure 28, A, B, D, and 
E).  When recovering from 0 mV, the effect of lidocaine on recovery from 
inactivation is similar for T1464I and WT channels while recovery from 
inactivation for I1461T channels is attenuated at long recovery durations (Figure 
28C).  This implies at -100 mV and -50 mV, I1461T and T1464I mutations 
decrease the stabilization of lidocaine interaction with the fast-inactivated state of 
the Nav1.7 channel and thus the recovery observed is a combination of channel 
recovery from a weaker lidocaine interaction and a less stable fast-inactivated 
state.  At 0 mV, it is possible the I1461T mutation makes the channel more 
effective at transitioning to a slow-inactivated state in the presence of lidocaine.  
This is reflected in a lower magnitude of recovery compared to lidocaine treated 
WT channels. 
10. The I1461T and T1464I mutations alter the onset of inactivation for 
Nav1.7 channels 
Using the protocol shown in Figure 29A, the onset of slow inactivation for I1461T 
and T1464I channels was compared to WT channels at -100 mV, -50 mV, and 0 
mV.  Table 8 displays the time constants for the onset of slow inactivation for the 
I1461T and T1464I channels compared to WT channels.  As expected, pulsing 
I1461T and T1464I channels to -100 mV for increasing durations does not induce 
a significant transition to a slow-inactivated state (Figure 29B).  Thus the small 
amount of recovery observed in Figure 26A is recovery of the I1461T and T1464I 
channels from a fast-inactivated state.  The induction of slow inactivation is  
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 Figure 28.  Comparison of lidocaine 
effects on the recovery from prolonged 
inactivation for WT, I1461T, and T1464I 
channels.  A—C, recovery profiles of Nav1.7 
WT, I1461T, and T1464I channels from 
different pre-pulse potentials in the presence 
of 1 mM lidocaine.  The pre-pulse value is 
given at the top of each graph.  For these 
experiments, the channels were held at the 
indicated potential for 10 seconds before 
recovery pulses to -120 mV at various 
durations were elicited.  This was followed 
by a 20 ms test pulse to 0 mV to test for 
available current.  All profiles were fit with 
either a first or second-order exponential 
growth equation.  All fits had R2 > 0.90. 
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evident in I1461T and T1464I channels when pulsing to potentials of -50 mV and 
0 mV (Figure 29, C and D).  Although not significant, the initial fraction of slow-
inactivated I1461T and T1464I channels appeared slightly attenuated compared 
to WT channels (Figure 29, C and D).  However, the fraction of slow-inactivated 
channels is increased for I1461T and T1464I channels compared to WT 
channels as the durations become prolonged (-50 mV: > 10s, 0 mV: > 2s; Figure 
29, C and D).  Overall, the profile for the onset of slow inactivation for I1461T and 
T1464I channels are very similar.  Interestingly, the recovery from inactivation 
profiles for I1461T and T1464I channels are much different in that recovery of 
I1461T channels after pulsing to potentials -50 and 0 mV was delayed compared 
to recovery of T1464I channels (Figure 26, C and D).  This indicates the I1461T 
and T1464I mutations alter transition of Nav1.7 to slow-inactivated state/s in a 
similar manner while affecting recovery from slow-inactivated state/s in a different 
manner. 
11.  The I1461T and T1464I mutations alter the onset of lidocaine 
inhibition for Nav1.7 channels   
Again using the protocol from Figure 29A, the effects of lidocaine on the 
onset of inactivation for I1461T and T1464I channels was tested.  When pulsing 
to -100 mV, no lidocaine inhibition was observed for I1461T (n = 3) channels 
(Figure 30A).  Only a small amount of lidocaine inhibition was observed for 
T1464I (n = 3) channels (Figure 30D).  When pulsing to -50 mV, lidocaine 
inhibition of channel current was faster than the onset of slow inactivation for 
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Figure 29.  The effects of the 
I1461T and T1464I mutation on 
the onset of slow inactivation for 
Nav1.7 channels.  A, Voltage 
protocol used to obtain the onset of 
slow inactivation profiles for I1461T 
and T1464I Nav1.7 channels.  B—D, 
time course for the onset of slow 
inactivation for Nav1.7 WT, I1461T, 
and T1464I channels from different 
pre-pulse potentials.  The pre-pulse 
value is given at the top of each 
graph.  For these experiments, the 
channels were held pulsed to the 
indicated potential for increasing 
durations before a recovery pulse to 
-120 mV for 30 or 40 ms was 
elicited.  This was followed by a 20 
ms test pulse to 0 mV to test for 
available current.  All profiles were 
fit with a second-order exponential 
decay equation.  All fits had R2 > 
0.90. 
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Table 8.  Estimated time constants of the onset of slow inactivation for 
Nav1.7 WT, I1461T, and T1464I channels. 
 
WT I1461T T1464I Pre-pulse 
voltage 
(mV) 
Tau  (ms) A Tau  (ms) A Tau (ms) A 
-100 mV N/A N/A N/A N/A N/A N/A 
-50 mV 540 +/- 50  0.45 800 +/- 130 0.37 640+/- 130 0.32
0 mV 340 +/- 52  0.53 660 +/- 390 0.34 480 +/- 280 0.29
 
Values are means estimated from the best fit line produced from a second-order 
exponential growth function.  The second-order exponential growth equation is 
as follows: 21 21
txtx
o eAeAyy ++=  where yo = the initial value at time 0, A1 = 
fraction of recovery at time τ1, A2 = fraction of recovery at τ2, x = the growth 
constant, and τ1 and τ2 = time constant for the recovery of fast and slow-
inactivated channels, respectively.   
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Figure 30.  Lidocaine effects on the onset of slow inactivation at various 
potentials for Nav1.7 channels having the I1461T or T1464I mutation.  The 
protocol used for examining onset of slow inactivation and lidocaine inhibition for 
I1461T (n = 3) and T1464I (n = 3) channels was the same as the one used in 
Figure 19.  The pulse value is given at the top of each graph.  The recovery pulse 
for -100 mV was to -120 mV for 30 ms.  The recovery pulse for -50 mV and 0 mV 
was to -120 mV for 40 ms.  The onset of slow inactivation for I1461T (A) and 
T1464I (D),and the onset of lidocaine inhibition for I1461T (A) were not analyzed 
by curve fitting due to no decrease in current.  All fits had R2 > 0.90. 
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I1461T (n = 3) and T1464I (n = 3) channels (Figure 30, B and E).  However, as 
the pulse duration reached close to 30 seconds, the magnitude of slow-
inactivated channels exceeds the amount of channels inhibited by lidocaine 
(Figure 30, B and E).  Consistent with results seen with WT channels, the rate of 
lidocaine inhibition for I1461T and T1464I channels reaches a plateau at 
approximately the same time that the onset of slow inactivation begins (Figure 
30, B and E).  When increasing the depolarizing pulse to 0 mV, the rate of 
lidocaine inhibition continued to be faster than the onset of slow inactivation for 
I1461T (n = 4) and T1464I (n = 3) channels (Figure 30, C and F).  In addition, 
lidocaine inhibition for I1461T and T1464I channels reaches a plateau similar to 
that observed at -50 mV.  However, at 0 mV a second component of current 
decay is observed in the presence of lidocaine for both I1461T and T1464I 
channels (Figure 30, C and F).  This most likely represents the onset of a slow-
inactivated state independent of lidocaine interaction with the channels.  The 
magnitude of decrease in current of this second component was also less than 
that observed in control channels.  This indicates lidocaine is impeding the 
transition of I1461T and T1464I channels to a second slow-inactivated state 
similar to that seen with WT channels.  However, in control channels the 
transition to two separate slow-inactivated states at 0 mV is not observed (Figure 
30, C and F). 
The effects of lidocaine on the onset of inactivation for WT, I1461T, and 
T1464I channels were also compared (Figure 31).  When pulsing to -100 mV, it is 
clear the I1461T and T1464I mutations decrease the ability of lidocaine to  
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Figure 31.  Comparison of lidocaine 
effects on the onset of slow 
inactivation for WT, I1461T, and T1464I 
channels.  A—C, time course for the 
onset of slow inactivation for Nav1.7 WT, 
I1461T (n = 3) and T1464I channels (n = 
3) at different pre-pulse potentials in the 
presence of 1 mM lidocaine.  The pre-
pulse value is given at the top of each 
graph.  For these experiments, the 
channels were held pulsed to the 
indicated potential for increasing 
durations before a recovery pulse to -120 
mV for 30 or 40 ms was elicited.  This 
was followed by a 20 ms test pulse to 0 
mV to test for available current.  All 
profiles were fit with either a first or 
second-order exponential decay 
equation.  All fits had R2 > 0.90. 
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produce channel inhibition (Figure 31A).  The T1464I mutation did not change 
the initial enhancement of channel inhibition by lidocaine when pulsing to -50 mV 
(Figure 31B).  However, as this pulse was extended the magnitude of inhibition 
was less for the T1464I channels than for WT channels (Figure 31B).  In 
contrast, the I1461T mutation delayed the initial enhancement of channel 
inhibition by lidocaine as well as decreasing the magnitude of inhibition at 
prolonged durations at -50 mV (Figure 31B).  The initial enhancement of channel 
inhibition by lidocaine did not seem to be affected by either mutation when 
pulsing to 0 mV (Figure 31C).  The I1461T mutation did however decrease the 
magnitude of lidocaine inhibition at durations between 30 ms and 1000 ms 
(Figure 31C).  As shown previously, lidocaine attenuates the fraction of WT 
channels inactivating at prolonged pulses (> 5 s) to 0 mV (Figure 19F).  The 
T1464I mutation does not alter this transition compared to WT channels (Figure 
31C).  However, in the presence of lidocaine, the I1461T mutation enhances the 
magnitude of channels transitioning to a slow-inactivated state in the presence of 
lidocaine (Figure 31C).  These results show that the I1461 and T1464 residues in 
Nav1.7 channels are important in stabilizing the interaction of lidocaine with the 
channel.  It also indicates the I1461 residue might be more important in this 
stabilization than the T1464 residue.  
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III. DISCUSSION 
This dissertation focused primarily on 3 aspects of the electrophysiological 
and pharmacological properties of the neuronal VGSC subtype Nav1.7.  The first 
dealt with the possibility that the antipsychotic drug TFP could modulate Nav1.7 
currents through disruption of the CaM-channel interaction.  Results showed TFP 
could directly interact with the Nav1.7 through the LA binding site of the channel.  
The second aspect of this dissertation was an extension of the TFP findings 
which involved using a point mutation (N434K) in rat Nav1.4 that affects LA and 
TFP interaction with VGSCs.  The corresponding mutation in Nav1.7 has been 
implicated in the painful neuropathy condition termed primary erythromelalgia.  
Therefore, it was predicted that the N395K mutation in Nav1.7 alters 
electrophysiological properties of the channel as well as the interaction of 
lidocaine with the channel.  The N395K Nav1.7 channel displayed an altered 
electrophysiological profile as well as a decreased sensitivity to lidocaine.  The 
third and final aspect of this dissertation investigated the interaction of the Nav1.7 
channel with the lidocaine.  Findings indicate lidocaine decreases channel 
transition to slow inactivation and the fast inactivation gate (DIII-DIV linker) is 
necessary for stabilizing the interaction of lidocaine with the Nav1.7 channel.  
Below is the detailed discussion of these results and how they impact Nav1.7 
pharmacology and electrophysiology.   
 
 119
A. Inhibition of Nav1.7 and Nav1.4 sodium channels by trifluoperazine (TFP) 
involves the local anesthetic interaction site 
In the first part of this dissertation, it was investigated whether the CaM 
inhibitor TFP can modulate Nav1.7 and Nav1.4 channels.  Although these 
channels may exhibit very different affinities for binding CaM (Herzog et al., 
2003b), TFP decreases current amplitude for both Nav1.7 and Nav1.4 and 
causes hyperpolarizing shifts in Nav1.7 and Nav1.4 steady-state inactivation while 
having no effect on the voltage-dependence of activation.  TFP also had use-
dependent inhibition effects on these channels which provides evidence that the 
predominant inhibitory effect of TFP is through interaction with the LA binding site 
of these channels.  These data indicate only a minor component of the TFP 
effect  is likely due to preventing CaM interaction with the channels.  This 
dissertation further reveals the mechanism of TFP inhibition by identifying 
specific amino acid residues involved in the interaction of TFP on closed and 
inactivated Nav1.4 channels.   
The initial hypothesis for this work was blocking CaM interactions with the 
C-terminus of these channels by using TFP would influence the gating of the 
channels.  However, the Nav1.4 currents, which were dramatically inhibited by 
TFP, were largely unaffected by the specific CaM inhibitor, CaM inhibitory 
peptide, at high concentrations (1 μM; KD = 6 pM).  The CaM inhibitory peptide 
did show significant effects on Nav1.7 steady-state inactivation, but the use-
dependent effects were much smaller than those induced by TFP.  This indicated 
while CaM could play a role in regulating steady-state inactivation of Nav1.7, the 
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more profound effect of TFP on Nav1.7 might be independent of CaM inhibition, 
suggesting TFP altered sodium currents through a different mechanism.  
Therefore, an alternative mechanism for the effects of TFP on Nav1.7 and Nav1.4 
was investigated.   
 Previous studies have reported several phenothiazine neuroleptics 
structurally related to TFP can also block sodium currents in a use-dependent 
manner (Ogata et al., 1990; Bolotina et al., 1992; Liu et al., 1992; Ahmmed et al., 
2002).  However, the ability of TFP and these other neuroleptics to directly 
interact with sodium channels, and the molecular mechanism of this possible 
drug-channel interaction, has not previously been determined.  LAs are known to 
produce hyperpolarizing shifts in steady-state inactivation and use-dependent 
inhibition of sodium currents by binding to a receptor site on the ion channel 
(Hille, 1977; Bean, et al., 1983).  These studies and the observations of TFP 
causing hyperpolarizing shifts in steady-state inactivation, exhibiting a higher 
interaction with inactivated channels, and exhibiting a concentration independent 
recovery from inhibition led to the hypothesis that TFP might interact with Nav1.7 
and Nav1.4 through the LA interaction site.  To test this TFP inhibition was tested 
on channels having three separate mutations in the S6 segments that disrupt LA 
inhibition.  The attenuation of the inhibitory effects of TFP on the N434K and 
F1579K mutant channel currents indicates these residues are important for the 
interaction of TFP with sodium channels and that TFP acts directly on the 
channel.  Surprisingly, the inhibitory effects of TFP on L1280K mutant channel 
current were greater than (Figure 12B) or equal to (Figure 12A) the effects on 
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WT Nav1.4.  Although this is different from the effect the L1280K mutation has on 
LA and amitriptyline binding, it is consistent with the hypothesis the TFP binding 
site and the LA binding site overlap.   
 The results show TFP preferentially interacts with the inactivated state of 
voltage-gated sodium channels compared to the closed state.  The N434K and 
F1579K mutant Nav1.4 channels showed a significantly decreased mean 
response to 500 nM TFP in their inactivated state indicating the binding of TFP to 
the channel is reliant on these 2 residues when the channel is inactivated.  
Interestingly, the L1280K channel showed no significant difference in the 
apparent affinity of the inactivated state.  However, inhibition of the L1280K 
channel in the closed state was potentiated compared to that of the wild-type, 
N434K, and F1579K channels.  This result indicates the L1280K mutation 
enhances the interaction of TFP to the closed-state and not the inactivated state 
of the channel.  Interestingly, it has been hypothesized the hydrophobic group of 
tertiary amine LAs interacts at the cytoplasmic mouth of the channel pore 
(Ragsdale et al., 1994).  This interaction is believed to be through hydrophobic 
interactions (Butterworth and Strichartz, 1990) between the aromatic groups of 
the LA and Phe and Tyr residues at the mouth of the channel pore.  However, it 
was further hypothesized mutating a Tyr residue (Y1586) in the Nav1.4 channel 
pore to a positively charged Lys residue could induce a cation-π electron 
interaction (Heginbotham and MacKinnon, 1992) and increase the interaction of 
benzocaine with the channel (Wright et al., 1998).  Therefore, it is possible that 
the L1280K mutation has somehow created an additional interaction site on the 
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resting Nav1.4 channel for one of the aromatic moieties of TFP.  This might 
explain the increased inhibitory effects of TFP on the resting state of the Nav1.4.  
However, further experiments, such as mutating the L1280 residue to an alanine, 
would be necessary to confirm this possibility. 
The data shows Nav1.4 in its inactivated state displays high interaction 
with TFP and the N434 and F1579 residues are important for this high interaction 
of TFP to the inactivated state of the sodium channel.  Furthermore, these results 
show that the L1280 residue has less involvement in the binding of TFP to the 
inactivated state of the channel than residues N434 and F1579.  However, these 
results also show that out of the N434, L1280, and F1579 residues, only the 
L1280 residue is important for TFP binding to the closed-state of voltage-gated 
sodium channels.  This is consistent with the L1280 residue being accessible by 
TFP in the closed-state while moving to an inaccessible position during activation 
and/or inactivation.   
Due to conserved homology between the Nav1.4 and Nav1.7 LA binding 
site, it was hypothesized the inhibitory effects of TFP on human Nav1.7 are due 
to direct interaction with this site.  Direct interaction with neuronal sodium 
channels could help explain the finding that TFP injections in sciatic nerve 
produces motor and sensory blockade (Sheets et al., 2006).  These findings 
were from experiments performed by Dr. Peter Gerner’s laboratory in the 
Department of Anesthesiology at Brigham and Women’s Hospital and Harvard 
Medical School.  The nerve block by TFP was found to be robust and more 
potent than lidocaine suggesting that TFP or TFP analogs might be useful for 
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inducing prolonged nerve block.  The ability of TFP to block Nav1.7 at low doses 
could make it a potential therapeutic regimen for regional anesthesia and pain 
management that would be more potent than traditional local anesthetics. 
Overall, these experiments show the inhibition of sodium current caused 
by TFP is largely independent of the inhibition of CaM.  The majority of the 
inhibition by TFP can be attributed to direct interaction of the drug with the 
sodium channels in a state-dependent manner.  Interestingly, TFP’s label as a 
potent CaM inhibitor has resulted in its effects being commonly related to 
inhibition of the CaM/CaMKII pathway.  Studies using TFP to inhibit CaM and its 
effectors could be overlooking the direct action of TFP on sodium channels.  This 
inhibitory action might lead to inaccurate conclusions regarding CaM’s 
involvement in physiological processes.  More specifically, studies correlating 
CaM inhibition with nerve block using TFP could be demonstrating a direct 
interaction of TFP with voltage-gated sodium channels highly expressed in 
peripheral nerves.   
B. A channel mutation associated with primary hereditary erythromelalgia 
(N395K) alters electrophysiological properties of Nav1.7 in addition to 
decreasing channel sensitivity to the local anesthetic lidocaine 
The decreased sensitivity of the N434K rat Nav1.4 channel to TFP led to 
the design of the second part of this dissertation.  As mentioned earlier, the 
N434K mutation in the rat Nav1.4 channel decreased the inhibitory effects of LAs 
(Wang et al., 2004a; Nau and Wang, 2004).  This same point mutation is found at 
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the homologous residue in the Nav1.7 channel (N395K) and is implicated in the 
painful inherited neuropathy erythromelalgia (Drenth et al., 2005).  Interestingly, 
one study showed treatment of primary erythromelalgia with lidocaine relieved 
pain in only 55% of afflicted patients (Davis and Sandroni, 2005).  These findings 
gave basis for investigating the effects of the N395K mutation on lidocaine 
inhibition of the Nav1.7 channel as well as the overall electrophysiological effects 
of this mutation on voltage-dependent properties of Nav1.7.   
Therefore, the second overall goal of this dissertation was to examine 
electrophysiological differences in Nav1.7 caused by the N395K mutation.  The 
hyperpolarizing shift in activation and slower onset of deactivation caused by 
N395K is similar to findings involving other hereditary erythromelalgia mutations 
(Cummins et al., 2004; Han et al., 2006; Harty et al., 2006).  All of the other 
erythromelalgia mutations studied to date (F216S, S241T, I848T, L858H, L858F, 
F1449V, and A863P) shift the voltage-dependence of activation in the negative 
direction by 7 to 14 mV (Cummins et al., 2004; Dib-Hajj et al., 2005; Choi et al., 
2006; Han et al., 2006; Harty et al., 2006; Lampert et al., 2006).  All of the 
mutations, with the exception of F1449V, also slow deactivation, but they differ in 
the manner in which they affect deactivation.  The N395K mutation, like the 
F216S mutation, simply shifts the voltage-dependence of the deactivation time 
constant curve in the negative direction in a manner that is consistent with the 
shift in activation.  By contrast, many of the other mutations, such as the L858H 
mutation, alter deactivation in a more pronounced voltage-dependent fashion 
(see Figure 1D of Cummins et al., 2004).  This suggests the different 
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erythromelalgia mutations alter Nav1.7 gating in at least two distinct ways.  The 
N395K mutation also caused impairment of steady-state slow inactivation which 
is seen with sodium channel mutations associated with disorders such as 
epilepsy, hyperkalemic periodic paralysis, and hereditary erythromelalgia 
(Cummins and Sigworth, 1996; Bendahhou et al., 1999; Bendahhou et al., 2002; 
Cummins et al., 2004; Rhodes et al., 2005).  However, only the I848T and N395K 
erythromelalgia mutations impair slow inactivation.  The F1449V mutation does 
not alter slow inactivation and the other erythromelalgia mutations enhance slow 
inactivation.  This differential effect on slow inactivation might indicate that slow 
inactivation is not important for the pathophysiology of erythromelalgia.  By 
contrast, the shift in activation is believed to decrease the threshold for action 
potential generation, leading to nociceptor hyperexcitability and chronic pain in 
erythromelalgia patients.   
The third goal of this dissertation was to determine whether the N395K 
mutation changes the effects of lidocaine on Nav1.7 current.  The N395 residue is 
located in the S6 segment of domain I and was proposed to lie within the local 
anesthetic binding site of Nav1.7.  One study has shown lidocaine relieved pain in 
only 55% of erythromelalgia patients (Davis and Sandroni, 2005) raising the 
possibility that specific mutations such as N395K in Nav1.7 might contribute to 
the unresponsiveness of some patients to lidocaine treatment.  Therefore, the 
hypothesis was mutation of this residue would reduce the inhibitory effects of 
lidocaine on channel current.  The results clearly demonstrate an attenuation of 
lidocaine inhibition on inactivated N395K channels at -50 mV.  This reduction of 
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the lidocaine effect was seen at all concentrations tested including 
concentrations comparable to total lidocaine serum concentrations (~ 10—16 
μM) that cause analgesia in neuropathic pain patients (Ferrante et al., 1996).  
Interestingly, the dose-response curve for lidocaine inhibition on Nav1.7 WT 
inactivated channels showed there were potentially two distinct inhibition trends 
and was best fit using a two-site binding model.  One possibility for this 
phenomenon is that holding the cell at -50 mV for prolonged periods of time 
causes a subset of channels to transition into a high affinity binding state and a 
subset into a low affinity binding state.  These two distinct states could involve 
closed-state and open-state inactivation which may have different affinities for 
lidocaine.  A recent study in the squid giant axon showed at -50 mV total 
inactivation is comprised of both closed-state and open-state inactivation 
(Armstrong, 2006).  The possibility that the ratio of closed-state versus open-
state inactivated channels during the prolonged -50 mV pre-pulse might explain 
the two-phase dose-inhibition curve for lidocaine on Nav1.7 WT inactivated 
channels and was the focus of the final section of this thesis.   
An alternative explanation for the two-phase dose-response of WT 
channels to lidocaine would be fast-inactivated and slow-inactivated states of 
Nav1.7 interact differently with lidocaine.  Indeed, one explanation for the 
reduction of lidocaine’s effect on the N395K channel is the mutation impairs 
steady-state slow inactivation and thus there are fewer channels in the 
inactivated state.  This could decrease the number of channels in a configuration 
that preferentially interact with lidocaine.  However, F216S channels display 
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enhanced steady-state inactivation at -50 mV (Choi et al., 2006) and, in the 
present study, did not show enhanced inhibition with lidocaine in the inactivated 
state compared to wild-type.  Furthermore, WT channels prepulsed to -70 mV for 
30s and N395K channels prepulsed to -50 mV for 30s both have approximately 
21% of their channels slow-inactivated (Figure 14B), yet WT channels still 
displayed a higher inhibition of channel current by lidocaine with a -70 mV 
prepulse than N395K channels with a -50 mV prepulse (data not shown).  This 
indicates the N395K mutation in Nav1.7 alters the direct interaction of lidocaine 
with the inactivated state of the channel, and suggests that changes in steady-
state slow inactivation might not affect lidocaine inhibition of the channel.  This 
was also investigated further in the final section of this thesis.  In addition, the 
inhibitory effect of lidocaine at high concentrations on the resting N395K channel 
was reduced compared to the resting WT channel.  This further confirms the 
N395K mutation affects the direct interaction of lidocaine with Nav1.7 because 
the percentage of total channels in the resting state would be the same for 
N395K and WT using a -140 mV pre-pulse.   
A recent study has reported loss of functional Nav1.7 channels in humans 
due to homozygous nonsense mutations leads to a complete inability to sense 
pain (Cox et al., 2006).  Surprisingly, individuals with this profound inability to 
sense pain were deemed to be healthy in virtually every other way.  Although 
Nav1.7 is believed to be present in both sensory and sympathetic ganglion 
neurons, none of the individuals studied by Cox et al. exhibited symptoms of 
autonomic nervous system dysfunction.  Furthermore, non-nociceptive sensory 
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functions appeared normal in the individuals with the homozygous nonsense 
mutations that eliminated functional Nav1.7 currents.  This study strongly 
indicates drugs that specifically target Nav1.7 could have the potential to 
selectively ameliorate pain.  Interestingly, it has been reported mice lacking 
Nav1.7 and Nav1.8 subtypes can develop neuropathic pain (Nassar et al., 2004) 
indicating Nav1.7 may not be important in the production of neuropathic pain.  To 
date, it has not been reported whether the humans lacking Nav1.7 function can 
develop neuropathic pain.  The fact that Nav1.7 has not been implicated in 
neuropathic pain suggests the intriguing possibility these individuals may in fact 
have the ability to develop some type of neuropathic pain.  Unfortunately, these 
individuals thus far have died very young (i.e. teenage years), and it is difficult to 
obtain this information at this time.   
The variability in the response of erythromelalgia patients to local 
anesthetics that target sodium channels may be due, at least in part, to differing 
effects of the various hereditary erythromelalgia mutations in Nav1.7 on lidocaine 
sensitivity.  The data collected in this dissertation predicts the individuals with the 
N395K mutation are likely to be more resistant to lidocaine treatment than 
individuals with the F216S mutation.  Genotype-phenotype correlations are 
needed to help determine if this is indeed the case.  Although none of the other 
hereditary erythromelalgia mutations identified thus far are located in the local 
anesthetic binding site, the possibility that one or more of these mutations also 
alters lidocaine sensitivity merits examination in future experiments.  
Interestingly, all of the hereditary erythromelalgia mutations studied to date, 
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including the N395K mutation studied here, induce a hyperpolarizing shift in the 
voltage-dependence of activation of Nav1.7 currents, suggesting this alteration is 
crucial to the development of the pain associated with hereditary erythromelalgia.  
It could be speculated other manipulations, such as phosphorylation, that might 
also induce hyperpolarizing shifts in activation could contribute to increased pain 
sensations.  Thus observations on the N395K mutation gathered in this 
dissertation provide insight into the changes in Nav1.7 channel activity 
contributing to abnormal pain sensations in erythromelalgia, and also suggest 
research focusing on the function and pharmacology of the Nav1.7 channel is 
crucial to the understanding of pain pathophysiology and the advancement of 
pain management therapies. 
C. Lidocaine stabilizes Nav1.7 in a configuration that decreases transition to 
the slow-inactivated state of the channel 
The two-site binding model gave a much better fit than the one-site 
binding model to the dose-response curve for lidocaine inhibition of Nav1.7 
channel current.  This fit indicated there are two states of Nav1.7 channels at -50 
mV, one state exhibiting a high interaction with lidocaine and the other exhibiting 
a low interaction.  To date there remains much debate as to the exact interaction 
of lidocaine with VGSCs.  One explanation for the two-site binding model is the 
long pulse used to evaluate lidocaine inhibition of Nav1.7 created fast and slow-
inactivated configurations of the channel, and lidocaine interacts differently with 
these two states of the channel.  Another possibility is a pulse to -50 mV creates 
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a mixture of closed-inactivated and open-inactivated configuration, and it is these 
two populations that have different interactions with lidocaine.  A third potential 
explanation would be Nav1.7 channels exist in a phosphorylated and 
unphosphorylated state in HEK293 cells and the interaction of lidocaine may be 
altered depending on the phosphorylation state of the channel.   
The final hypothesis for this dissertation was the high affinity and low 
affinity populations represent channels in different inactivated conformations.  
Based on this hypothesis, the goals for the final part of this dissertation were to 
1) determine how different inactivated conformations of Nav1.7 affect lidocaine 
inhibition of the channel and 2) use PEPD mutations (I1461T and T1464I) that 
alter transitions between the different inactivated configurations of Nav1.7 to 
determine how these alterations affect lidocaine’s ability to inhibit channel 
current. 
The first step in examining the effects of lidocaine on the Nav1.7 channel 
was to establish recovery from fast and slow inactivation as well as from a 
lidocaine inhibited state.  Recovery from fast and slow inactivation was 
dependent on the pulse potential used to inactivate the channels.  The 
magnitude of channels recovering from inactivation became greater as the test 
pulse became more depolarized.  Recovery from lidocaine inhibition displayed a 
single-exponential growth profile that was slower than the recovery from fast 
inactivation but faster than the recovery from slow inactivation.  Interestingly, at 
depolarized conditioning pulse potentials (-50, -40 and 0 mV), the magnitude of 
recovery from lidocaine inhibited channels was greater than that observed for 
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slow-inactivated channels under control conditions.  This suggests the interaction 
of lidocaine with Nav1.7 is impairing the transition of the channel to a slow-
inactivated state and, therefore following prolonged depolarizations, channels 
recover faster and are available for activation sooner in the presence of 
lidocaine.  Lidocaine is likely stabilizing Nav1.7 into a drug-channel confirmation 
that is energetically favorable and transition to a slow-inactivated state is less 
favorable. 
Lidocaine also affects Nav1.7 channels when using protocols that evaluate 
slow inactivation.  Lidocaine increased the transition to a non-conducting state 
(likely a drug bound state) when compared to the onset of slow inactivation for 
Nav1.7 channels (Figure 19, Tables 3 and 4).  This was evident at all pulse 
potentials.  After the initial fast decrease in current caused by lidocaine 
interaction with the channel, the inhibition levels off and very little additional drop 
in current is observed.  This leveling off occurs at approximately the same time 
the onset of slow inactivation begins in control Nav1.7 channels indicating 
transition to a slow-inactivated state possibly hinders further inhibition of channel 
current by lidocaine.  This provides more evidence that lidocaine interacts with 
these fast-inactivated channels and transition to a slow-inactivated state is 
attenuated.  This explains why in the presence of lidocaine 1) the Nav1.7 current 
inhibition plateaus and 2) no additional decrease in Nav1.7 current in observed 
due to slow inactivation.  However, the second slow-inactivated state observed at 
very prolonged pulse durations still occurs in the presence of lidocaine 
demonstrating a slow-inactivated state of Nav1.7 that can occur even with the 
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channel is the presence of lidocaine.  However, these results did not answer if 
the initial slow-inactivated state is the low interaction configuration for lidocaine 
observed in the dose-response curve of Figure 15A.  Thus, another approach 
was used to investigate this possibility.   
The approach used to answer the hypothesis that the high lidocaine 
interaction and low lidocaine interaction states represent channels in different 
inactivated conformations was to observe the effects of different pulse potentials 
and durations (200 ms versus 10 s) on the dose-response relationship of 
lidocaine and Nav1.7.  The rationale was different pulse potentials would alter the 
fraction of channels in a closed fast-inactivated state versus open fast-inactivated 
state and different pulse durations would alter the proportion of fast versus slow-
inactivated channels.  However, the results suggest the two-site binding profile 
observed in Figure 15A for WT Nav1.7 channels is not due to a mixture of closed 
fast-inactivated and open fast-inactivated channels.  This is because at pulse 
potentials that would give a mixture of closed fast-inactivated and open fast-
inactivated channels (i.e. -60, -50, and -40 mV) the dose-response relationship 
fits a one-site binding profile.  This also indicates the increased potency of 
lidocaine caused by increased depolarization of the 200 ms pulse potential is due 
to a higher probability of the Nav1.7 channel being in the fast-inactivated state 
irrespective of closed fast-inactivated versus open fast-inactivated. 
The dose-response relationship of lidocaine and Nav1.7 channels after 
being pulsed to various potentials for 10 s resulted in very different effects than 
those observed with the 200 ms pulse.  The increase in pulse duration changed 
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the dose-response relationship from one-site binding profile to a two-site binding 
profile for all pulse potentials (Figure 20C).  Surprisingly, as the pulse potentials 
become more depolarized the dose-response curves for the 10 s pulse and the 
200 ms pulse intersect with higher lidocaine concentrations showing more 
inhibition on Nav1.7 channels pulsed for 200 ms than ones pulsed for 10 s (e.g. 
Figure 21F).  This suggests prolonging the pulse duration increases the 
probability of the Nav1.7 channel transitioning to a slow-inactivated state that 
displays less interaction with lidocaine than does fast-inactivated channels.   
An interesting finding is the estimated IC50 value (4.3 mM) for lidocaine on 
resting Nav1.7 channels (pulsed to -140 mV; Figure 15B) and the estimated IC50 
value (4.3 mM) for the second component of lidocaine inhibition on inactivated 
Nav1.7 channels (pulsed to -50 mV; Figure 15A) are identical.  The estimated 
IC50 values for the second component of lidocaine inhibition on Nav1.7 channels 
pulsed to various potentials for 10 s are also similar to the value observed for 
resting Nav1.7.  This indicates the pore configuration of Nav1.7 channels in a 
slow-inactivated state may be similar to the pore configuration of resting 
channels.   
As mention earlier, a recent study (Fertleman et al., 2006) reported three 
missense mutations in the SCN9A gene encoding for Nav1.7 which are linked to 
PEPD, a familial rectal pain syndrome, do not cause a hyperpolarizing shift in 
activation, but rather impair fast inactivation.  It is intriguing that Nav1.7 mutations 
predominantly associated with rectal pain may consistently impair fast 
inactivation while mutations predominantly associated with burning pain 
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sensations in the hands and feet cause a hyperpolarizing shift in activation.  
Since PEPD mutations are thought to alter transitions between the different 
configurations of Nav1.7, they can be used as tools to further understand the 
state-dependent inhibition of channel current by lidocaine.  Two mutations 
implicated in PEPD, I1461T and T1464I, were inserted separately in the Nav1.7 
channel, and the effects of these mutations on channel function and lidocaine 
interaction were investigated.  In contrast to what is observed in erythromelalgia 
mutations of Nav1.7 channels, the I1461T and T1464I mutations showed no 
effect on the voltage-dependence of activation.  However, the I1461T and T1464I 
mutations do decrease the ability of lidocaine to effectively inhibit channel 
current.   
Since no affect of the I1461T and T1464I mutations could be observed on 
activation of Nav1.7, it was likely this decrease in lidocaine inhibition of the 
channel was due to a decreased interaction with the inactivated state of the 
channel.  These mutations lie within the DIII-DIV cytoplasmic linker and the 
attenuated voltage-dependence of fast inactivation and enhanced persistent 
component during inactivation for Nav1.7 channels having either of the mutations 
confirms the importance of the DIII-DIV cytoplasmic linker in fast inactivation of 
VGSCs.  The presence of a noticeable persistent component during the 
inactivation element of I1461T and T1464I current traces supports that these 
mutations attenuate the ability of the Nav1.7 channel to completely inactivate.  
Interestingly, the I1461T and T1464I mutations did not affect the overall 
enhancement of fast-inactivation by lidocaine.  Lidocaine created a similar shift in 
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the voltage-dependence of fast inactivation for WT, I1461T, and T1464I 
channels.  Since these mutations do not lie within what is thought to be the LA 
interaction site of the channel, this means the interaction of lidocaine with the LA 
site must remain intact.  But the question still remains as to why these mutant 
channels are displaying a decreased sensitivity to lidocaine?  Thus, the effects of 
the I1461T and T1464I mutations on Nav1.7 voltage-dependence of slow 
inactivation as well as lidocaine interaction with Nav1.7 during slow inactivation 
protocols were examined.   
The I1461T and T1464I mutations did affect the voltage-dependence of 
slow inactivation but in a very interesting manner.  Both mutations caused 
attenuation in the extent of slow inactivation for Nav1.7 channels at potentials 
ranging from -90 mV to -60 mV.  However, once the pulse potential was 
depolarized to -50 mV or lower, the voltage-dependence of slow inactivation for 
I1461T channels was enhanced while T1464I channels displayed no difference 
from WT channels.  Overall, the I1461T and T1464I mutations eliminate the two-
phase profile for the voltage-dependence of slow inactivation of Nav1.7 channels.  
This indicates the I1461 and T1464 residues play a role determining which slow-
inactivated configuration the Nav1.7 channel will be in at a given voltage.   
Lidocaine enhances the voltage-dependence of slow inactivation/drug 
inhibition for I1461T and T1464I channels less than WT channels.  In addition, 
this enhancement is only observed at potentials more hyperpolarized than -40 
mV for both mutations.  Thus, the presence of the I1461T and T1464I mutations 
alter lidocaine interaction with the channel after prolonged pulse durations and 
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allow for lidocaine to decrease the magnitude of channels transitioning to a slow-
inactivated state at depolarized potentials compared to control channels.  One 
thing to note is this protocol does have a repolarization step to allow for the relief 
of fast-inactivated channels which would involve the removal of the fast 
inactivation gate.  Thus the I1461T and T1464I mutations may alter lidocaine 
interaction during the repolarization of the Nav1.7 channel.  This would explain 
why use-dependent decreases in current amplitude by lidocaine in I1461T and 
T1464I channels were significantly smaller than the decrease observed in the 
WT channel. 
The time course of recovery from fast inactivation for I1461T and T1464I 
channels was slightly faster than that observed for WT channels after pre-pulsing 
to -100 mV for 10 s indicating the I1461T and T1464I channels are not stabilizing 
in a fast-inactivated state as completely as WT channels.  Surprisingly, the 
I1461T channels recovered more slowly than WT channels after prolonged 
inactivation at -50 and 0 mV (Figure 26, C and D).  By contrast the T1464I 
channels recover no differently than WT channels at the longer recovery 
durations (Figure 26, C and D).  It has been hypothesized that fast inactivation 
state of VGSCs can decrease the transition of the channel to a subsequent slow 
inactivation state after alteration of the fast inactivation gate (DIII-DIV cytoplasmic 
linker) by intracellular proteolysis or mutation (Valenzuela and Bennett, Jr., 1994; 
Featherstone et al., 1996).  Therefore, I1461T channels likely transition to the 
slow-inactivated state more readily due to a decreased ability of the channel to 
fast inactivate.   
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The effects of lidocaine on the recovery of I1461T and T1464I channels 
from inactivation were tested to further understand how lidocaine may be 
interacting with the Nav1.7 channel.  The most interesting observation was that 
lidocaine increases recovery of I1461T channels from from fast and slow 
inactivation (Figure 27, B and C).  As shown in WT channels, at depolarized 
conditioning pulse potentials, the magnitude of recovery from lidocaine inhibited 
channels was greater than that observed for channels under control conditions, 
providing additional evidence that the interaction of lidocaine with Nav1.7 is 
prohibiting the transition of the channel to a slow-inactivated state.  The same 
can be suggested for the interaction of lidocaine with I1461T and T1464I 
channels.  In addition, the delayed recovery of I1461T channels from lidocaine 
inhibition compared to WT channels (Figure 28C) shows that while lidocaine is 
delaying the transition to slow inactivation in WT channels, the I1461T mutation 
can attenuate this effect due to less stabilization of lidocaine interaction. 
The I1461T and T1464I mutations also showed effects on the onset of 
slow inactivation in Nav1.7 channels.  As mentioned earlier, it is thought that 
decreasing the ability of the channel to stabilize in a fast-inactivated state may 
allow for a more effective transition to a slow-inactivated state.  Thus, channels 
would transition to the slow-inactivated state more readily due to a decreased 
ability of the channel to fast inactivate.  However, it was observed that I1461T 
and T1464I transition to a slow-inactivated state less than WT channels until 
reaching longer pulse durations where they slow-inactivated more.  This 
suggests the Nav1.7 channel’s transition to an initial or first slow-inactivated state 
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is slightly hindered when the I1461 and T1464 are mutated.  However, transition 
to the second slow-inactivated state seems to be enhanced when the same two 
mutations are present.   
The main focus of these experiments was to investigate the effects of 
lidocaine on the onset of slow inactivation in Nav1.7 channels.  Interestingly, for 
the I1461T and T1464I channels an initial fast decrease in current caused by 
lidocaine interaction with the channel was observed, and just as with WT 
channels, the inhibition levels off and very little additional drop in current is 
observed (Figure 30).  Yet, when the conditioning pulse is 0 mV, lidocaine seems 
to attenuate the transition of the I1461T and T1464I channels at prolonged 
durations.  This demonstrates lidocaine is diminishing the transition of the 
channels to the potential second slow-inactivated state observed at prolonged 
pulse durations.  When looking at the effects of lidocaine on the onset of 
lidocaine inhibition for WT, I1461T, and T1464I channels together, it is clear the 
I1461T and T1464I mutations decrease the magnitude of lidocaine inhibition.  
This once again demonstrates the I1461 and T1464 residues in Nav1.7 channels 
are critical in stabilizing the interaction of lidocaine with the channel.  The 
observation that the T1464I mutation does not have an effect on the initial onset 
of lidocaine inhibition shows that the T1464 residue, while critical for fast 
inactivation, may not be as important in lidocaine stabilization as the I1461 
residue.   
Taken together, these data suggest that while the closure of the fast 
inactivation gate is not absolutely necessary for lidocaine interaction with Nav1.7, 
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the fast inactivation gate of Nav1.7 is critical in the stabilization of the high 
lidocaine interaction with the channel.  Figure 32 displays a theorectical 
schematic of how lidocaine interaction with the Nav1.7 channel may be taking 
place.  These data also show interaction of lidocaine with VGSCs can be altered 
by mutations that lie outside of the theoretical LA binding site of the channel.  
Moreover, the fact the channel mutations used in these final experiments are 
implicated in PEPD suggests LA treatment for these patients may less affective.   
The two-site binding model used to fit the dose-response curve for 
lidocaine inhibition of Nav1.7 was likely a result of lidocaine having different 
affinities for the fast-inactivated configuration versus the slow-inactivated 
configuration of the channel.  The explanation that lidocaine interacts with closed 
fast-inactivated and open fast-inactivated channels differently is unlikely due to 
dose-response response curves using 200 ms conditioning pulses fitting better 
with a one-site binding profile.  This also decreases the possibility that the 
interaction of lidocaine is altered due to different phosphorylated states of the 
channel which theoretically would be independent of pulse duration.  However, 
differences in lidocaine interaction with Nav1.7 due to phosphorylation of the 
channel was not tested directly and still needs to be examined.  Overall, the 
results from the last aim of this dissertation indicate the interaction of lidocaine 
with Nav1.7 creates a drug-channel confirmation that is energetically favorable 
compared to fast inactivation, and if lidocaine is bound, transition to a slow-
inactivated state is less probable.  Furthermore, Nav1.7 channels in the initial 
slow-inactivated state may very well be in a confirmation that has a similar 
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Figure 32.  Theoretical schematic of lidocaine interaction with the Nav1.7 
channel.  The top of the schematic represents simplified configurations of a 
Nav1.7 channel at the instant before lidocaine interaction.  The middle of 
schematic represents a modified form the of inactivation model (Armstrong and 
Gilly, 1979) with a theoretical level of lidocaine interaction with each state.  As 
shown in the diagram as the channel transitions closer to the open state, the 
model suggests that lidocaine interaction increases.  In addition, the model 
suggests recovery from the drug bound/inactivated (‘CI or ‘OI) decreases as the 
channel transitions closer to the open state.  In other words, the stabilization of 
lidocaine by the inactivation gate is greater when lidocaine can fully access its 
high affinity interaction site of the open channel.  The bottom of the schematic 
represents simplified Nav1.7 channel-lidocaine interactions induced from closed, 
partially activated (but still closed), and open channel configurations. 
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lidocaine interaction site to resting channels.  Thus, slow inactivation takes place 
in a region of the Nav1.7 channel that is not important for lidocaine interaction at 
high concentration. 
D. Summation and future directions 
Results from this dissertation demonstrate 1) TFP inhibits Nav1.7 channels 
through the LA interaction site, 2) the N395K mutation alters electrophysiological 
properties of Nav1.7 and decreases channel sensitivity to the local anesthetic 
lidocaine, 3) lidocaine stabilizes Nav1.7 in a configuration that decreases 
transition to the slow-inactivated state of the channel, and 4) the fast inactivation 
gate of Nav1.7 is critical in the stabilization of the high lidocaine interaction with 
the channel.  Overall, this dissertation answers important questions regarding the 
pharmacology of Nav1.7 and provides insight into the changes in Nav1.7 channel 
properties caused by point mutations that may contribute to abnormal pain 
sensations.  The results of this dissertation on the function and pharmacology of 
the Nav1.7 channel are crucial to the understanding of pain pathophysiology and 
will provide insight for the advancement of pain management therapies.    
An extension of this dissertation would involve mutating the phenylalanine 
of the IFM peptide in the inactivation loop to a cysteine that could be modified by 
methanethiosulfonate (MTS) derivatives.  This modification would interfere with 
the inactivation peptide reaching its interaction site in the channel pore thus 
eliminating fast inactivation.  The effect of lidocaine in the presence and absence 
of MTS would provide further evidence to the importance of the inactivation gate 
 142
in lidocaine stabilization.  Much is still unknown as to how the Nav1.7 may be 
modified during inflammation or nerve injury including expression and/or 
posttranslational modification (i.e. phosphorylation).  As shown by mutation, 
changing the voltage-dependent properties of the Nav1.7 is a factor that can lead 
to aberrant activity of nociceptive neurons.  Understanding potential modulation 
of Nav1.7 brought on by inflammation, injury, or other conditions such as cancer 
or cancer treatment would be helpful in understanding how these conditions 
affect the activity of sensory neurons and potentially lead to pain.  In addition, 
studies could be done to alter the phosphorylated states of VGSCs and observe 
the role of these states in the pharmacology of the channel.  Furthermore, the 
structure-function relationship of the various gating mechanisms that VGSCs 
undergo also remains unclear.  Mutagenesis of VGSCs, while insightful, does not 
truly answer what is structurally important for the transition between the different 
gating mechanisms.  Molecular modeling has been helpful in this area, but until a 
complete crystal structure is produced for VGSCs, the structure-function 
relationship of the various gating mechanisms cannot be confirmed.  
Advancements in these areas would be important in designing more selective 
and adequate pain therapeutics.   
Overall, this dissertation answers important questions regarding the 
pharmacology and biophysics of the Nav1.7 channel.  This channel is fascinating 
in that removal of its function in the human body leads to the inability to sense 
pain thus creating a captivating and potential target for the treatment of pain.  
Furthermore, the role of Nav1.7 (and VGSCs in general) in human physiology 
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remains intriguing and a continued effort to understand these roles is a critical 
step in discovering new ways to improve the quality and longevity of life.   
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